WO2010031183A1 - Indole derivatives as crth2 receptor antagonists - Google Patents

Indole derivatives as crth2 receptor antagonists Download PDF

Info

Publication number
WO2010031183A1
WO2010031183A1 PCT/CA2009/001321 CA2009001321W WO2010031183A1 WO 2010031183 A1 WO2010031183 A1 WO 2010031183A1 CA 2009001321 W CA2009001321 W CA 2009001321W WO 2010031183 A1 WO2010031183 A1 WO 2010031183A1
Authority
WO
WIPO (PCT)
Prior art keywords
indol
amino
acetic acid
methyl
tetrahydropyrido
Prior art date
Application number
PCT/CA2009/001321
Other languages
French (fr)
Inventor
John Colucci
Michael Boyd
Mohamed Helmi Zaghdane
Original Assignee
Merck Frosst Canada Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.
Priority to AU2009295230A priority Critical patent/AU2009295230A1/en
Priority to CA2737483A priority patent/CA2737483A1/en
Priority to JP2011527166A priority patent/JP2012502927A/en
Priority to US13/120,074 priority patent/US8637671B2/en
Priority to EP09813945.4A priority patent/EP2346865B1/en
Publication of WO2010031183A1 publication Critical patent/WO2010031183A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Definitions

  • Prostaglandin D2 is a cyclooxygenase metabolite of arachidonic acid. It is released from mast and TH2 cells in response to an immunological challenge, and has been implicated in playing a role in different physiological events such as sleep and allergic responses.
  • Receptors for PGD2 include the "DP” receptor, the chemoattractant receptor- homologous molecule expressed on TH2 cells (“CRTH2”), and the "FP" receptor.
  • CRTH2 receptors are G-protein coupled receptors activated by PGD2.
  • the CRTH2 receptor and its expression on different cells including human T-helper cells, basophils, and eosinophils are described in Abe, et al, Gene 227:11-11, 1999, Nagata, et al, FEBS Letters 459:195-199, 1999, and Nagata, et al, The Journal of Immunology 162: 1278- 1286, 1999, describe CRTH2 receptor.
  • Hirai, et al, J. Exp. Med. 193:255-261, 2001 indicates that CRTH2 is a receptor for PGD2.
  • WO2007019675 discloses CRTH2 antagonists of the formula:
  • the present invention provides novel compounds which are CRTH2 receptor 20 antagonists.
  • Compounds of the present invention are useful for the treatment of various prostaglandin-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of prostaglandin-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them.
  • the present invention relates to compounds of formula I: MCC-BRE-00003
  • Z is -C(O)-(C(Rd)(Re)) n - or -C(O)-C(Rf)(Rg)-O-, wherein n is 0, 1 or 2;
  • Cy is aryl, heteroaryl or C3.6 cycloalkyl optionally fused to a benzene, each of which is optionally substituted with 1 to 4 groups independently selected from R c ; 10 R 1 is selected from H, halogen, -OC 1 -6alkyl, and -C 1 -6alkyl;
  • R2 is selected from H, halogen, -Ci-6alkyl, -OCi-6alkyl, -SCi_6alkyl, -S(O)Q -6alkyl, -
  • R ⁇ is selected from H, Ci-6alkyl and benzyl optionally substituted on the phenyl portion with 1 to 3 halogen; 15 Ra and Rb are independently H, aryl, heteroaryl, C 1. ⁇ alkyl or haloC 1 -6alkyl; or
  • Ra and Rb together with the carbon atom to which they are both attached form a C3-6cycloalkyl ring;
  • Ra and Rb together with the adjacent carbon atoms to which they are attached form a C3. 6cycloalkyl ring;
  • Re is selected from halogen, NRfRg, S ⁇ 2NRfRg, CN, C 1 -6alkoxy, C 1 -6alkyl, haloC 1 -6alkoxy, and haloC 1 -6alkyl;
  • Rd and R e are independently selected from hydrogen, Ci-6alkyl, -Ci-6alkyl-C3-6cycloalkyl, hydroxy, C ⁇ alkoxy, NRfRg, and aryl optionally substituted with 1 to 3 groups independently; or 25 Rd, Re together with the carbon atom to which they are both attached form a C3_6cycloalkyl optionally having a ring heteroatom selected from -O-, -S-, -N(C(O)Rf)- and -N(Rf)-, and optionally substituted with 1 to 3 Ci-3alkyl groups; or
  • Rd Re attached to adjacent carbon atoms together with the carbon atoms to which they are attached form a C3_6cycloalkyl optionally having a ring heteroatom selected from -O-, -S-, - 30 N(C(O)Rf)- and -N(Rf)-, and optionally substituted with 1 to 3 Ci -3alkyl groups; and Rf and Rg are independently selected from hydrogen and Ci-3alkyl; or Rf Rg together with the atom to which they are both attached form a 3- to 6-membered ring.
  • Cy is phenyl optionally substituted with 1 to 3 groups independently selected from Rc.
  • Cy is phenyl optionally substituted with 1 to 2 groups independently selected from halogen, Ci_6alkyl, haloCi- ⁇ alkyl and Ci_6alkoxy.
  • Rd and R e are other than hydrogen.
  • Rd, Re and the carbon to which they are both attached together form a C3-6carbocycle optionally substituted with one or two Ci_3alkyl groups.
  • R3 is other than hydgrogen; in one group thereof R3 is methyl.
  • the invention also encompasses pharmaceutical compositions containing a 20 compound of formula I, and methods for treatment or prevention of prostaglandin mediated diseases using compounds of formula I.
  • halogen or halo includes F, Cl, Br, and I. MCC-BRE-00003
  • alkyl refers to linear or branched alkyl chains having the indicated number of carbon atoms.
  • alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl, hexyl, and the like.
  • Haloalkyl means an alkyl group as described above wherein one or more 5 hydrogen atoms have been replaced by halogen atoms, with up to complete substitution of all hydrogen atoms with halo groups.
  • Ci_6haloalkyl for example, includes -CF3, -CF2CF3, CHFCH3, and the like.
  • Alkoxy means alkoxy groups of a linear or branched alkyl chain having the indicated number of carbon atoms. Ci-6alkoxy, for example, includes methoxy, ethoxy,
  • Haloalkoxy means an alkoxy group as described above in which one or more hydrogen atoms have been replaced by halogen atoms, with up to complete substitution of all hydrogen atoms with halo groups.
  • Ci-6haloalkoxy for example, includes -OCF3, -OCF2CF3, - OCH2CF3 and the like.
  • Aryl means a 6-14 membered carbocyclic aromatic ring system comprising 1-3 benzene rings. If two or more aromatic rings are present, then the rings are fused together, so that adjacent rings share a common bond. Examples include phenyl and naphthyl.
  • Het heteroaryl
  • Het represents a 5-10 membered aromatic ring system containing one ring or two fused rings, 1 -4 heteroatoms, selected from O, S and N.
  • Het includes, but is not limited to, furanyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazolyl, pyridyl, pyrrolyl, tetrazolyl, thiazolyl, thiadiazolyl, thienyl, triazinyl, triazolyl, 7H-pyrrole-2,5-dionyl, 2-pyrone, 4-pyrone, pyrrolopyridine, furopyridine and thienopyridine.
  • “Therapeutically effective amount” means that amount of a drug or
  • treatment includes alleviating, ameliorating, relieving or otherwise reducing the signs and symptoms associated with a disease or disorder.
  • composition as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of
  • compositions of the present invention encompass any composition made by admixing a compound of formula I, and pharmaceutically acceptable excipients.
  • optionally substituted means "unsubstituted or substituted," and therefore, the generic structural formulas described herein encompasses compounds containing the specified optional substituent as well as compounds that do not contain the optional substituent.
  • aryl or heteroaryl each optionally substituted with 1 to 4 5 groups independently selected from R c encompasses unsubstituted aryl or heteroaryl, and aryl or heteroaryl substituted with one, two, three or four substituents selected from R c ; the same phrase can also be represented by the equivalent expression "Ar-(R c ) ⁇ -4".
  • each R c is independently selected at each occurrence, and each R c can be the same or different from the other(s).
  • the term -OC(Ci-3alkyl)2- includes compounds in which the two alkyl substituents are of the same or different chain lengths.
  • each occurrence of Rd and R e can be the same or different from the other occurrence of Rd and R e , respectively; for example, -(C(Rd)(Re))2- can be -
  • Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers. 35 Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of formula I. MCC-BRE-00003
  • Compounds of the formula I may be separated into diastereo isomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof.
  • a suitable solvent for example methanol or ethyl acetate or a mixture thereof.
  • the pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an 5 optically active acid as a resolving agent.
  • any enantiomer of a compound of the general formula I may be obtained by stereo specific synthesis using optically pure starting materials or reagents of known configuration.
  • salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.
  • ammonium, calcium, magnesium, potassium, and sodium salts are particularly preferred.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
  • salts may be prepared from
  • non-toxic acids including inorganic and organic acids.
  • Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid, and the like.
  • Particularly preferred are citric, hydrobromic, hydrochloric,
  • references to the compound of formula I, Ia, Ib, Ic and Id, subsets thereof, embodiments thereof, as well as specific compounds are meant to also include the pharmaceutically acceptable salts.
  • prostaglandin receptors The ability of compounds of formula I to interact with prostaglandin receptors makes them useful for preventing or reversing undesirable symptoms caused by prostaglandins in 5 a mammalian, especially human subject.
  • This mimicking or antagonism of the actions of prostaglandins indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent, or ameliorate in mammals and especially in humans: respiratory conditions, allergic conditions, pain, inflammatory conditions, mucus secretion disorders, bone disorders, sleep disorders, fertility disorders, blood coagulation disorders, trouble of the vision as well as
  • Such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer.
  • Compounds of formula I may also be of use in the treatment and/or prevention prostaglandin- mediated proliferation disorders such as may occur in diabetic retinopathy and tumor angiogenesis.
  • Compounds of formula I may also inhibit prostanoid-induced smooth muscle
  • compounds of formula I are antagonists of prostaglandin D2 receptor, CRTH2.
  • another aspect of the invention provides a method of treating or preventing a prostaglandin mediated disease comprising administering to a mammalian patient in
  • Prostaglandin mediated diseases include, but are not limited to, allergic rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma including allergic asthma, chronic obstructive pulmonary diseases and other forms of lung inflammation; sleep disorders and sleep-wake cycle disorders; prostanoid-
  • bone formation and resorption such as for example osteoporosis; shock; thermal regulation including fever; and immune disorders or conditions in which immunoregulation is desirable.
  • the disease to be treated is one mediated by prostaglandin D2 such as nasal congestion, pulmonary congestion, and asthma including allergic asthma.
  • 35 prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula I in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein the prostaglandin mediated disease is nasal congestion, rhinitis including allergic and perennial rhinitis, and asthma including allergic asthma.
  • the prostaglandin mediated disease is nasal congestion, rhinitis including allergic and perennial rhinitis, and asthma including allergic asthma.
  • in another embodiment of the present invention is a method of treating or preventing a prostaglandin D2-mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula I in an amount which is effective for treating or preventing a prostaglandin D2 mediated disease wherein said prostaglandin D2 5 mediated disease is nasal congestion or asthma.
  • in another embodiment of the present invention is a method for the treatment of nasal congestion in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of formula I.
  • in yet another embodiment of the present invention is a method for the treatment 10 of asthma, including allergic asthma, in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of formula I.
  • the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • 25 humans may contain from 0.05 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 99.95 percent of the total composition.
  • Dosage unit forms will generally contain between from about 0.1 mg to about 0.4 g of an active ingredient, typically 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, or 400 mg.
  • compositions comprising a compound of formula I with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier for the treatment of any of the prostanoid mediated diseases compounds of formula I may be
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc.
  • the compound of the invention is effective in the treatment of humans.
  • compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, 5 dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and
  • Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets.
  • excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and
  • lubricating agents for example, magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108;
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for
  • Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting
  • 30 agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene- oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of
  • aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, MCC-BRE-00003
  • flavouring agents such as sucrose, saccharin or aspartame.
  • sweetening agents such as sucrose, saccharin or aspartame.
  • Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such 5 as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
  • compositions of the invention may also be in the form of an
  • the oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these.
  • Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example
  • the emulsions may also contain sweetening and flavouring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
  • sweetening agents for example glycerol, propylene glycol, sorbitol or sucrose.
  • Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents.
  • the pharmaceutical compositions may be in
  • a sterile injectable aqueous or oleagenous suspension This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3 -butane diol.
  • a non-toxic parenterally-acceptable diluent or solvent for example as a solution in 1,3 -butane diol.
  • solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • compositions may also be administered in the form of suppositories for rectal administration of the drug.
  • These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the MCC-BRE-00003
  • rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.
  • compound of formula I may be co-administered with other therapeutic agents.
  • the present invention provides pharmaceutical compositions for treating prostaglandin mediated diseases comprising a therapeutically effective amount of a compound of formula I and one or more other therapeutic agents. Suitable therapeutic agents for combination therapy with a
  • compound of formula I include: (1) a DP receptor antagonist such as S-5751 ; (2) a corticosteroid such as triamcinolone acetonide; (3) a ⁇ -agonist such as salmeterol, formoterol, terbutaline, metaproterenol, albuterol and the like; (4) a leukotriene modifier, including a leukotriene receptor antagonist such as montelukast, zafirlukast, pranlukast, or a lipooxygenase inhibitor including 5 -lipooxygenase inhibitors and FLAP (5 -lipooxygenase activating protein) inhibitors
  • an antihistamine such as bromopheniramine, chlorpheniramine, dexchlor- pheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripelennamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like; (6) a decongestant including phenylephrine, phenyl-
  • proanolamine pseudophedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine
  • an antitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan
  • another prostaglandin ligand including prostaglandin F agonist such as latanoprost; misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol
  • NSAIDs non-steroidal antiinflammatory agents
  • propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin,
  • fenamic acid derivatives flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid
  • biphenylcarboxylic acid derivatives diiflunisal and flufenisal
  • oxicams isoxicam, piroxicam, sudoxicam and tenoxican
  • salicylates acetyl salicylic acid, sulfasalazine
  • pyrazolones Japanese, bezpiperylon, feprazone, mofebutazone, MCC-BRE-00003
  • oxyphenbutazone oxyphenbutazone, phenylbutazone
  • COX-2 cyclooxygenase-2
  • PDE-IV phosphodiesterase type IV
  • Ariflo, roflumilast (13) antagonists of the chemokine receptors, especially CCR-I, CCR-2, and CCR-3; (14) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin and 5 pravastatin, fluvastatin, atorvastatin, and other statins), sequestrants (cholestyramine and colestipol), nicotinic acid, fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzaf ⁇ brate), and probucol; (15) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), ⁇ -glucosidase inhibitors (acarbose) and glitazones (troglitazone, pioglitazone, englitazone, rosiglitazone and the like);
  • interferon beta-lb 10 interferon beta-lb);
  • anticholinergic agents such as muscarinic antagonists (ipratropium bromide and tiotropium bromide), as well as selective muscarinic M3 antagonists;
  • steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone;
  • triptans commonly used for the treatment of migraine such as sumitriptan and rizatriptan; (20) alendronate and other treatments for osteoporosis; (21) other compounds
  • WO 15 such as 5-aminosalicylic acid and prodrugs thereof, antimetabolites such as azathioprine and 6- mercaptopurine, cytotoxic cancer chemotherapeutic agents, bradykinin (BK2) antagonists such as FK-3657, TP receptor antagonists such as seratrodast, neurokinin antagonists (NK1/NK2), VLA- 4 antagonists such as those described in US 5,510,332, WO97/03094, WO97/02289, WO96/40781, WO96/22966, WO96/20216, WO96/01644, WO96/06108, WO95/15973 and
  • BK2 bradykinin
  • TP receptor antagonists such as seratrodast
  • NK1/NK2 neurokinin antagonists
  • VLA- 4 antagonists such as those described in US 5,510,332, WO97/03094, WO97/02289, WO96/40781, WO96/22966, WO96
  • the invention encompasses a method of treating prostaglandin D2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of formula I, optionally co-administered with one or more of such ingredients as listed immediately above.
  • the amine I can be alkylated, for example with an alkyl iodide in the
  • Step 1 ethyl 3-(6-oxo- 1 -phenyl-1 AS. ⁇ -tetrahvdropyridazin-B-vDpropanoate
  • Step 2 propyl 3 - [3 -(2-oxo-2-propoxyethyl)- 1 //-mdol-2-yl]propanoate
  • Methanesulfonic acid (1.15 equiv.) was added to a stirred solution of ethyl 3-(6- oxo-l-phenyl-l,4,5,6-tetrahydropyridazin-3-yl)propanoate from Step 1 in n-propanol (1.1 M).
  • N-methylmorpholine (1.1 equiv.) was added dropwise over Ih to a stirred, 0 0 C mixture of 3-[3-(2-oxo-2-propoxyethyl)-lH-indol-2-yl]propanoic acid from Step 3 and ethyl chloroformate (1.11 equiv.) in T ⁇ F (0.4 M).
  • the reaction temperature was closely monitored during the addition and was not allowed to go over +2 0 C.
  • the mixture was stirred at 0 0 C an additional 30min. A white precipitate formed rapidly.
  • Diazomethane (0.3 M in Et 2 O, 1.8 equiv.)
  • Rhodium (II) octanoate dimmer (0.1 equiv.) was added to a CH 2 Cl 2 solution (0.02 M) of propyl [2-(4-diazo-3-oxobutyl)-lH-indol-3-yl]acetate from Step 4. The reaction mixture was stirred overnight at rt and then concentrated. The residue was purified by column chromatography on silica gel using automatized gradiant pump system CombiFlashRF (Teledyne
  • indol-10-yl)acetate from Step 5 was added as a DMSO (0.06 M) solution.
  • the reaction was adjusted to pH 7.2 and aged at 30 0 C overnight under nitrogen atmosphere.
  • the pH of the reaction was adjusted to pH 4.0 with 6N HCl and Celite (20 g per L) was added.
  • the combined aqueous filtrate was extracted with 1 volume of MTBE.
  • the organic layer did not contain amine and was discarded.
  • the aqueous layer was diluted with an equal volume of MTBE and the pH of the mixture was adjusted to pH 9.5 using 5N NaOH.
  • the two phases were separated and the aqueous layer was extracted with MTBE.
  • the spent aqueous layer had no detectable amine and was discarded.
  • the 10 combined organic layers were washed with dilute sodium carbonate and dried over Na 2 SO 4 .
  • R 3 a R 3 group other than H such as methyl
  • R lower alkyl (methyl, ethyl, propyl, etc )
  • MS mass spectra
  • Step 1 Propyl r(7i?)-7-(methylaminoV6.7,8.9-tetrahvdropyrido ⁇ .2- ⁇ 1indol-10-yllacetate
  • Step 2 Preparation of 2-(4-fluorophenyl)propanoic acid.
  • Methyl (4-fluorophenyl)acetate 0.5 g was dissolved in DMF (81 niL). The mixture was cooled in an ice bath and NaH (131 mg, 60% w/w in mineral oil) was added. The 5 mixture was stirred for 1 h at RT and again cooled in an ice bath before the addition of MeI (633 mg). The mixture was warmed to RT and, the reaction was quenched with 1/2 (sat.) aqueous ammonium chloride. Work up consisted of extraction of the aqueous layer with ether (2 x). The combined organic fractions were washed with water and brine, then dried (MgSCU). The solvent was evaporated under reduced pressure and methyl 2-(4-fluorophenyl)propanoate was purified on
  • Example 1 (20.0 mg) was dissolved in DCM (2.0 mL) then DMAP (0.449 mg), (4-fluoro- phenyl)acetyl chloride (16.0 ⁇ L) and triethylamine (10.24 ⁇ L) were added to the solution under MCC-BRE-00003
  • Example 1 (Method A) from (2,4-difluorophenyl)acetic acid and propyl [(7 ⁇ )-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 413.
  • Example 1 (Method A) from indane-1-carboxylic acid and propyl [(7i?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 403.
  • Example 2 (Method B) from 4-fluorobenzoyl chloride and propyl [(77?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2-fl]indol-10-yl]acetate. MS (+ESI) m/z: 381.
  • Example 2 (Method B) from cyclopropanecarboxylic acid and propyl [(7/?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 327.
  • Example 2 (Method B) from l-(4-chlorophenyl)cyclopentanecarbonyl chloride and propyl [(7R)- 7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate.
  • Example 1 (Method A) from 1 -(4-fluorophenyl)cyclopropanecarboxylic acid and propyl [(7i?)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-(3]indol-10-yl]acetate. MS (+ESI) m/z: 321.
  • Example 1 (Method A) from (4-fluorophenyl)(piperidin-l-yl)acetic acid and propyl [(7 R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate.
  • Example 1 (Method A) from methoxy(phenyl)acetic acid and propyl [(7i?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 407.
  • Example 1 (Method A) from (2-methyl-l,3-thiazol-4-yl)acetic acid and propyl [(7R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-fl]indol-10-yl]acetate. MS (+ESI) m/z: 398.
  • Example 1 (Method A) from 3-cyclopropyl-2-(4-fluorophenyl)propanoic acid and propyl [(I R)- 7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 449.
  • Step 1 propyl [(7/?)-7-(ethylaminoV6.7.8.9-tetrahydropyrido[l .2- ⁇ lindol-l O-yl]acetate This compound was achieved according to the general procedures outlined in
  • Step 2 ((7/?)-7-(Ethyl-[l-(4-fluoro-phenylVcvclopropanecarbonyl]-aminoj-6J,8,9- tetrahydro-pyrido [ 1 ,2-a]indol- 10-ylV acetic acid
  • Step 1 methyl 17-ilY4-fluorophenvDsulfonyll (methvDamino) -6.7.8.9-
  • Step 2 methyl r(7 ⁇ -7- ⁇ r(4-fluorophenvnsulfonyl ⁇ methyl)aminol-6.7.8.9- tetrahvdropyrido [ 1 ,2-a] indol- 10-yl] acetate 15
  • the methyl [7- ⁇ [(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9- tetrahydropyrido[l,2- ⁇ ]indol-10-yl ⁇ acetate was resolved by chiral HPLC using a ChiralpakAD column and eluting with a mixture of 20%EtOH/20%z ' PrOH/60%Hex to afford equal amounts of methyl [(7S)-7- ⁇ [(4-fluorophenyl)sulfonyl] (methyl)amino ⁇ -6,7,8,9-tetrahydropyr
  • Step 3 methyl [(7y>-7-(methylamino)-6.7,8,9-tetrahydropyridori.2-fl1indol-10-yl]acetate
  • Step 4 r(7 ⁇ )-7-ir(4-fluorophenyl)acetyll(methyl)amino ⁇ -6.7.8.9-tetrahvdropyridori.2- a] indol- 10-yl] acetic acid
  • Example 1 (Method A) from 4-(4-fluorophenyl)tetrahydro-2H-pyran-4-carboxylic acid and propyl [(7i?)-7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 465.
  • Example 1 (Method A) from 1,2,3,4-tetrahydronaphthalene-l-carboxylic acid and propyl [(7R)- 7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 417.
  • Example 1 (Method A) from cyclopentylacetic acid and propyl [(7i?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 369.
  • Example 1 (Method A) from 2-(pyridin-2-yl)propanoic acid and propyl [(7J?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2- ⁇ ]indol-10-yl]acetate. MS (+ESI) m/z: 392.
  • Step 1 7-fluoroindole
  • This compound was prepared from 2-fluoro-phenylhydrazine according to the
  • This compound was prepared from 7-fluoroindole according to the general procedures outlined in Example 1 (step 1 and 2).
  • Radioligand binding assay Radioligand binding assays were performed at room temperature in 10 niM HEPES/KOH pH 7.4, ImM EDTA containing 1OmM MnCl 2 and 0.7 nM 5 [ 3 H]PGD 2 (NEN, 171 Ci mmol "1 ), in a final volume of 0.2 ml. Competing ligands were diluted in dimethylsulfoxide (Me 2 SO) that was kept constant at 1% (v/v) of the final incubation volume. The reaction was initiated by the addition of 8-20 ⁇ g of membrane protein prepared from a HEK- hCRTH2 cell line. Total and non-specific binding were determined in the absence and the presence of 10 ⁇ M PGD 2 , respectively. Under these conditions, specific binding (total minus
  • Ki (in nM) values for representative compounds of the present invention are as follows: ⁇ 5: Examples 1, 3, 5, 6, 20, 30, 31, 32, 35; >5 and ⁇ 10: Examples, 2, 26, 29; >10 and ⁇ 50: Examples 9, 19, 21, 23, 25, 36; >50 and ⁇ 100: Examples 7, 34. ifcAMP] measurements.
  • HEK-hCRTH2 cells were grown to 80-90% confluency.
  • the cells were washed with PBS, incubated for 2 min in cell dissociation buffer, harvested by centrifugation at 300g for 5 min at room temperature and resuspended at 1.25elO 6 cells ml "1 in Hanks' balanced salt solution containing 20 mM HEPES pH 7.4 and 0.75 mM IBMX (HBSS/HEPES/IBMX).
  • the assay was performed in 384-plate format with 0.01 ml HBSS/HEPES/IBMX per well containing 12 500 cells and 75 nl of the test compound at various
  • Eosinophil shape change assay in human whole blood Blood was collected in vacutainers containing EDTA. The antagonist was added to blood and incubated for 10 min at room temperature. DK-PGD 2 (13,14-dihydro-15-keto prostaglandin D 2 ) was then added to blood for 4 min at 37 0 C in a running water bath. Blood cells were then fixed in presence of cold
  • cytometry raw data were analyzed with FlowJo software by isolating the eosinophils from the neutrophils based on their high autofluorescence and determining the percent of total eosinophils with increased FSC-H value. Maximum (100%) and minimum (0%) shape change were determined in the presence of lO ⁇ M DK-PGD 2 and PBS, respectively.
  • a dose response curve 5 with DK-PGD 2 was performed with every assay to determine the EC 50 for each blood donor. Compounds were tested in 10-dose titration curves in the presence of 3OnM DK-PGD 2 to determine an antagonist IC 50 .
  • Some compounds of the present invention are selective for the CRTH2 receptor over the DP receptor. Assays on the DP, as well as other prostanoid, receptors are described in 10 WO2003/06220.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compound of formula I are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-mediated diseases such as asthma.

Description

MCC-BRE-00003
TITLE OF THE INVENTION
INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS
BACKGROUND OF THE INVENTION
Prostaglandin D2 (PGD2) is a cyclooxygenase metabolite of arachidonic acid. It is released from mast and TH2 cells in response to an immunological challenge, and has been implicated in playing a role in different physiological events such as sleep and allergic responses.
Receptors for PGD2 include the "DP" receptor, the chemoattractant receptor- homologous molecule expressed on TH2 cells ("CRTH2"), and the "FP" receptor. These
10 receptors are G-protein coupled receptors activated by PGD2. The CRTH2 receptor and its expression on different cells including human T-helper cells, basophils, and eosinophils are described in Abe, et al, Gene 227:11-11, 1999, Nagata, et al, FEBS Letters 459:195-199, 1999, and Nagata, et al, The Journal of Immunology 162: 1278- 1286, 1999, describe CRTH2 receptor. Hirai, et al, J. Exp. Med. 193:255-261, 2001, indicates that CRTH2 is a receptor for PGD2.
15 WO2007019675 discloses CRTH2 antagonists of the formula:
Figure imgf000002_0001
SUMMARY OF THE INVENTION
The present invention provides novel compounds which are CRTH2 receptor 20 antagonists. Compounds of the present invention are useful for the treatment of various prostaglandin-mediated diseases and disorders; accordingly the present invention provides a method for the treatment of prostaglandin-mediated diseases using the novel compounds described herein, as well as pharmaceutical compositions containing them.
25 DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to compounds of formula I: MCC-BRE-00003
Figure imgf000003_0001
I and pharmaceutically acceptable salts thereof, wherein:
Y is selected from -C(Ra)(Rb)., -C(Ra)(Rb)-C(Ra)(Rb)-, -C(Ra)=C(Rb)-, -OCH2-, -OCH(Ci-
5 3alkyl)-, -OC(Ci-3alkyl)2-, -OC(CH2)2-5-, -SCH2-, -SCH(C l-3alkyl)-, -SC(Ci_3alkyl)2- and -
SC(CH2)2-5-;
Z is -C(O)-(C(Rd)(Re))n- or -C(O)-C(Rf)(Rg)-O-, wherein n is 0, 1 or 2;
Cy is aryl, heteroaryl or C3.6 cycloalkyl optionally fused to a benzene, each of which is optionally substituted with 1 to 4 groups independently selected from Rc; 10 R1 is selected from H, halogen, -OC 1 -6alkyl, and -C 1 -6alkyl;
R2 is selected from H, halogen, -Ci-6alkyl, -OCi-6alkyl, -SCi_6alkyl, -S(O)Q -6alkyl, -
S(O)2Ci_6alkyl, -CN, aryl and heteroaryl;
R^ is selected from H, Ci-6alkyl and benzyl optionally substituted on the phenyl portion with 1 to 3 halogen; 15 Ra and Rb are independently H, aryl, heteroaryl, C 1.βalkyl or haloC 1 -6alkyl; or
Ra and Rb together with the carbon atom to which they are both attached form a C3-6cycloalkyl ring; or
Ra and Rb together with the adjacent carbon atoms to which they are attached form a C3. 6cycloalkyl ring;
20 Re is selected from halogen, NRfRg, Sθ2NRfRg, CN, C 1 -6alkoxy, C 1 -6alkyl, haloC 1 -6alkoxy, and haloC 1 -6alkyl;
Rd and Re are independently selected from hydrogen, Ci-6alkyl, -Ci-6alkyl-C3-6cycloalkyl, hydroxy, Cμβalkoxy, NRfRg, and aryl optionally substituted with 1 to 3 groups independently; or 25 Rd, Re together with the carbon atom to which they are both attached form a C3_6cycloalkyl optionally having a ring heteroatom selected from -O-, -S-, -N(C(O)Rf)- and -N(Rf)-, and optionally substituted with 1 to 3 Ci-3alkyl groups; or
Rd, Re attached to adjacent carbon atoms together with the carbon atoms to which they are attached form a C3_6cycloalkyl optionally having a ring heteroatom selected from -O-, -S-, - 30 N(C(O)Rf)- and -N(Rf)-, and optionally substituted with 1 to 3 Ci -3alkyl groups; and Rf and Rg are independently selected from hydrogen and Ci-3alkyl; or Rf Rg together with the atom to which they are both attached form a 3- to 6-membered ring. MCC-BRE-00003
In one subset of formula I are compounds wherein Cy is phenyl optionally substituted with 1 to 3 groups independently selected from Rc. In one embodiment thereof Cy is phenyl optionally substituted with 1 to 2 groups independently selected from halogen, Ci_6alkyl, haloCi-όalkyl and Ci_6alkoxy.
In another subset of formula I are compounds wherein Y is -C(Ra)(Rb)-. In one embodiment thereof Y is methylene.
In another subset of formula I are compounds wherein the chiral carbon to which the -NR3-Z-Cy is attached has the (^-configuration.
In another subset of formula I are compounds of formula Ia:
Figure imgf000004_0001
Ia In another subset of formula I are compounds of formula Ib:
Figure imgf000004_0002
Ib
15 In one embodiment, at least one of Rd and Re is other than hydrogen. In another embodiment Rd, Re and the carbon to which they are both attached together form a C3-6carbocycle optionally substituted with one or two Ci_3alkyl groups. In another embodiment R3 is other than hydgrogen; in one group thereof R3 is methyl.
The invention also encompasses pharmaceutical compositions containing a 20 compound of formula I, and methods for treatment or prevention of prostaglandin mediated diseases using compounds of formula I.
The invention is described using the following definitions unless otherwise indicated.
The term "halogen" or "halo" includes F, Cl, Br, and I. MCC-BRE-00003
The term "alkyl" refers to linear or branched alkyl chains having the indicated number of carbon atoms. Non-limiting examples of alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl, hexyl, and the like.
"Haloalkyl" means an alkyl group as described above wherein one or more 5 hydrogen atoms have been replaced by halogen atoms, with up to complete substitution of all hydrogen atoms with halo groups. Ci_6haloalkyl, for example, includes -CF3, -CF2CF3, CHFCH3, and the like.
"Alkoxy" means alkoxy groups of a linear or branched alkyl chain having the indicated number of carbon atoms. Ci-6alkoxy, for example, includes methoxy, ethoxy,
10 propoxy, isopropoxy, and the like.
"Haloalkoxy" means an alkoxy group as described above in which one or more hydrogen atoms have been replaced by halogen atoms, with up to complete substitution of all hydrogen atoms with halo groups. Ci-6haloalkoxy, for example, includes -OCF3, -OCF2CF3, - OCH2CF3 and the like.
15 "Aryl" means a 6-14 membered carbocyclic aromatic ring system comprising 1-3 benzene rings. If two or more aromatic rings are present, then the rings are fused together, so that adjacent rings share a common bond. Examples include phenyl and naphthyl.
The term "heteroaryl" (Het) as used herein represents a 5-10 membered aromatic ring system containing one ring or two fused rings, 1 -4 heteroatoms, selected from O, S and N.
20 Het includes, but is not limited to, furanyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, pyrazolyl, pyridyl, pyrrolyl, tetrazolyl, thiazolyl, thiadiazolyl, thienyl, triazinyl, triazolyl, 7H-pyrrole-2,5-dionyl, 2-pyrone, 4-pyrone, pyrrolopyridine, furopyridine and thienopyridine.
"Therapeutically effective amount" means that amount of a drug or
25 pharmaceutical agent that will elicit the biological or medical response of a tissue, a system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician.
The term "treatment" or "treating" includes alleviating, ameliorating, relieving or otherwise reducing the signs and symptoms associated with a disease or disorder.
30 The term "composition", as in pharmaceutical composition, is intended to encompass a product comprising the active ingredient(s), and the inert ingredient(s) (pharmaceutically acceptable excipients) that make up the carrier, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of
35 reactions or interactions of one or more of the ingredients. Accordingly, the pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of formula I, and pharmaceutically acceptable excipients. MCC-BRE-00003
The term "optionally substituted" means "unsubstituted or substituted," and therefore, the generic structural formulas described herein encompasses compounds containing the specified optional substituent as well as compounds that do not contain the optional substituent. For example, the phrase "aryl or heteroaryl each optionally substituted with 1 to 4 5 groups independently selected from Rc" encompasses unsubstituted aryl or heteroaryl, and aryl or heteroaryl substituted with one, two, three or four substituents selected from Rc; the same phrase can also be represented by the equivalent expression "Ar-(Rc)θ-4".
Each variable is independently defined each time it occurs within the generic structural formula definitions. For example, when there is more than one Rc in "Ar-(Rc)θ-4"
10 each Rc is independently selected at each occurrence, and each Rc can be the same or different from the other(s). In another example, the term -OC(Ci-3alkyl)2- includes compounds in which the two alkyl substituents are of the same or different chain lengths. As a further example, for the term -(C(Rd)(Re))n-5 when n is 2, each occurrence of Rd and Re can be the same or different from the other occurrence of Rd and Re, respectively; for example, -(C(Rd)(Re))2- can be -
15 CH2CH2-, -CH(CH3)CH2, -C(CH2)4CH2-, and the like.
For purposes of this specification, the following abbreviations have the indicated meanings Ac = acetyl; ADD = azodicarboxylic acid dipiperidide; BOC = t-butoxycarbonyl; DCM = dichloromethane; DIPEA = diisopropylethylamine; DMAP - 4-(dimethylamino)- pyridine; DMF = dimethylformamide; DMSO = dimethyl sulfoxide; HATU = O-(7-azabenzo-
20 triazol-l-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; MTBE = methyl t-butyl ether; NAD = β-nicotinamide adenine dinucleotide; PPTS = pyridinium p-toluene sulfonate; RT or rt = room temperature; TBAF = tetrabutylammonium fluoride; TBDMSi = t-butyldimethylsilyl; TEA = triethylamine; TFA = trifluoroacetic acid; THF = tetrahydrofuran;. Alkyl group abbreviations include: Me = methyl; Et = ethyl; n-Pr = normal propyl; i-Pr = isopropyl; c-Pr = cyclopropyl; n-
25 Bu = normal butyl; i-Bu = isobutyl; c-Bu = cyclobutyl; s-Bu = secondary butyl; t-Bu = tertiary butyl.
Optical Isomers - Diastereomers - Geometric Isomers - Tautomers
Compounds of formula I contain one or more asymmetric centers and can thus 30 occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of formula I.
Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z geometric isomers. 35 Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixture thereof are encompassed with compounds of formula I. MCC-BRE-00003
Compounds of the formula I may be separated into diastereo isomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an 5 optically active acid as a resolving agent.
Alternatively, any enantiomer of a compound of the general formula I may be obtained by stereo specific synthesis using optically pure starting materials or reagents of known configuration.
10 Salts
The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.
15 Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts.
Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol,
20 ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
When the compound of the present invention is basic, salts may be prepared from
25 pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p- toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric,
30 maleic, phosphoric, sulfuric, and tartaric acids.
It will be understood that, unless otherwise specified, references to the compound of formula I, Ia, Ib, Ic and Id, subsets thereof, embodiments thereof, as well as specific compounds are meant to also include the pharmaceutically acceptable salts.
Furthermore, some of the crystalline forms for compounds of the present
35 invention may exist as polymorphs and as such all forms are intended to be included in the present invention. In addition, some of the compounds of the instant invention may form solvates with water (hydrates) or common organic solvents. Such solvates are encompassed within the scope of this invention. MCC-BRE-00003
Utilities
The ability of compounds of formula I to interact with prostaglandin receptors makes them useful for preventing or reversing undesirable symptoms caused by prostaglandins in 5 a mammalian, especially human subject. This mimicking or antagonism of the actions of prostaglandins indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent, or ameliorate in mammals and especially in humans: respiratory conditions, allergic conditions, pain, inflammatory conditions, mucus secretion disorders, bone disorders, sleep disorders, fertility disorders, blood coagulation disorders, trouble of the vision as well as
10 immune and autoimmune diseases. In addition, such a compound may inhibit cellular neoplastic transformations and metastic tumor growth and hence can be used in the treatment of cancer. Compounds of formula I may also be of use in the treatment and/or prevention prostaglandin- mediated proliferation disorders such as may occur in diabetic retinopathy and tumor angiogenesis. Compounds of formula I may also inhibit prostanoid-induced smooth muscle
15 contraction by antagonizing contractile prostanoids or mimicking relaxing prostanoids and hence may be used in the treatment of dysmenorrhea, premature labor and eosinophil related disorders. More particularly compounds of formula I are antagonists of prostaglandin D2 receptor, CRTH2.
Accordingly, another aspect of the invention provides a method of treating or preventing a prostaglandin mediated disease comprising administering to a mammalian patient in
20 need of such treatment a compound of formula I in an amount which is effective for treating or preventing said prostaglandin mediated disease. Prostaglandin mediated diseases include, but are not limited to, allergic rhinitis, nasal congestion, rhinorrhea, perennial rhinitis, nasal inflammation, asthma including allergic asthma, chronic obstructive pulmonary diseases and other forms of lung inflammation; sleep disorders and sleep-wake cycle disorders; prostanoid-
25 induced smooth muscle contraction associated with dysmenorrhea and premature labor; eosinophil related disorders; thrombosis; glaucoma and vision disorders; occlusive vascular diseases; congestive heart failure; diseases or conditions requiring a treatment of anti-coagulation such as post-injury or post surgery treatment; inflammation; gangrene; Raynaud's disease; mucus secretion disorders including cytoprotection; pain and migraine; diseases requiring control of
30 bone formation and resorption such as for example osteoporosis; shock; thermal regulation including fever; and immune disorders or conditions in which immunoregulation is desirable. More particularly the disease to be treated is one mediated by prostaglandin D2 such as nasal congestion, pulmonary congestion, and asthma including allergic asthma.
In one embodiment of the invention is a method of treating or preventing a
35 prostaglandin mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula I in an amount which is effective for treating or preventing a prostaglandin mediated disease, wherein the prostaglandin mediated disease is nasal congestion, rhinitis including allergic and perennial rhinitis, and asthma including allergic asthma. MCC-BRE-00003
In another embodiment of the present invention is a method of treating or preventing a prostaglandin D2-mediated disease comprising administering to a mammalian patient in need of such treatment a compound of formula I in an amount which is effective for treating or preventing a prostaglandin D2 mediated disease wherein said prostaglandin D2 5 mediated disease is nasal congestion or asthma.
In another embodiment of the present invention is a method for the treatment of nasal congestion in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of formula I.
In yet another embodiment of the present invention is a method for the treatment 10 of asthma, including allergic asthma, in a patient in need of such treatment which comprises administering to said patient a therapeutically effective amount of a compound of formula I.
Dose Ranges
The magnitude of prophylactic or therapeutic dose of a compound of formula I
15 will, of course, vary with the nature and the severity of the condition to be treated and with the particular compound of formula I and its route of administration. It will also vary according to a variety of factors including the age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and response of the individual patient. In general, the daily dose from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to
20 about 10 mg per kg. On the other hand, it may be necessary to use dosages outside these limits in some cases.
The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a formulation intended for the oral administration of
25 humans may contain from 0.05 mg to 5 g of active agent compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 99.95 percent of the total composition. Dosage unit forms will generally contain between from about 0.1 mg to about 0.4 g of an active ingredient, typically 0.5 mg, 1 mg, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, or 400 mg.
30
Pharmaceutical Compositions
Another aspect of the present invention provides pharmaceutical compositions comprising a compound of formula I with a pharmaceutically acceptable carrier. For the treatment of any of the prostanoid mediated diseases compounds of formula I may be
35 administered orally, by inhalation spray, topically, parenterally or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. In addition to the treatment of warm- MCC-BRE-00003
blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, etc., the compound of the invention is effective in the treatment of humans.
The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, 5 dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavouring agents, colouring agents and preserving agents in order to provide pharmaceutically elegant and
10 palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and
15 lubricating agents, for example, magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the technique described in the U.S. Patent 4,256,108;
20 4,166,452; and 4,265,874 to form osmotic therapeutic tablets for control release.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredients is mixed with water-miscible solvents such as propylene glycol, PEGs and ethanol, or an oil medium, for
25 example peanut oil, liquid paraffin, or olive oil.
Aqueous suspensions contain the active material in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting
30 agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethylene- oxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of
35 ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more colouring agents, MCC-BRE-00003
one or more flavouring agents, and one or more sweetening agents, such as sucrose, saccharin or aspartame.
Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in mineral oil such 5 as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavouring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.
Dispersible powders and granules suitable for preparation of an aqueous
10 suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavouring and colouring agents, may also be present.
The pharmaceutical compositions of the invention may also be in the form of an
15 oil-in- water emulsion. The oily phase may be a vegetable oil, for example olive oil or arachis oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol anhydrides, for example sorbitan monooleate, and condensation products of the said partial esters with ethylene oxide, for example
20 polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavouring agents.
Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavouring and colouring agents. The pharmaceutical compositions may be in
25 the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3 -butane diol. Among the acceptable vehicles and
30 solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Cosolvents such as ethanol, propylene glycol or polyethylene glycols may also be used. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.
35 Compounds of formula I may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ambient temperatures but liquid at the MCC-BRE-00003
rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
For topical use, creams, ointments, gels, solutions or suspensions, etc., containing the compound of formula I are employed. (For purposes of this application, topical application 5 shall include mouth washes and gargles.) Topical formulations may generally be comprised of a pharmaceutical carrier, cosolvent, emulsifier, penetration enhancer, preservative system, and emollient.
Combinations with Other Drugs
10 For the treatment and prevention of prostaglandin mediated diseases, compound of formula I may be co-administered with other therapeutic agents. Thus in another aspect the present invention provides pharmaceutical compositions for treating prostaglandin mediated diseases comprising a therapeutically effective amount of a compound of formula I and one or more other therapeutic agents. Suitable therapeutic agents for combination therapy with a
15 compound of formula I include: (1) a DP receptor antagonist such as S-5751 ; (2) a corticosteroid such as triamcinolone acetonide; (3) a β-agonist such as salmeterol, formoterol, terbutaline, metaproterenol, albuterol and the like; (4) a leukotriene modifier, including a leukotriene receptor antagonist such as montelukast, zafirlukast, pranlukast, or a lipooxygenase inhibitor including 5 -lipooxygenase inhibitors and FLAP (5 -lipooxygenase activating protein) inhibitors
20 such as zileuton; (5) an antihistamine such as bromopheniramine, chlorpheniramine, dexchlor- pheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripelennamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like; (6) a decongestant including phenylephrine, phenyl-
25 propanolamine, pseudophedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; (7) an antitussive including codeine, hydrocodone, caramiphen, carbetapentane, or dextramethorphan; (8) another prostaglandin ligand including prostaglandin F agonist such as latanoprost; misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; (9) a diuretic; (10) non-steroidal antiinflammatory agents (NSAIDs) such as
30 propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin,
35 and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxican), salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, MCC-BRE-00003
oxyphenbutazone, phenylbutazone); (11) cyclooxygenase-2 (COX-2) inhibitors such as celecoxib and rofecoxib; (12) inhibitors of phosphodiesterase type IV (PDE-IV) e.g. Ariflo, roflumilast; (13) antagonists of the chemokine receptors, especially CCR-I, CCR-2, and CCR-3; (14) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin and 5 pravastatin, fluvastatin, atorvastatin, and other statins), sequestrants (cholestyramine and colestipol), nicotinic acid, fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzafϊbrate), and probucol; (15) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), α-glucosidase inhibitors (acarbose) and glitazones (troglitazone, pioglitazone, englitazone, rosiglitazone and the like); (16) preparations of interferon beta (interferon beta- Ia,
10 interferon beta-lb); (17) anticholinergic agents such as muscarinic antagonists (ipratropium bromide and tiotropium bromide), as well as selective muscarinic M3 antagonists; (18) steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone; (19) triptans commonly used for the treatment of migraine such as sumitriptan and rizatriptan; (20) alendronate and other treatments for osteoporosis; (21) other compounds
15 such as 5-aminosalicylic acid and prodrugs thereof, antimetabolites such as azathioprine and 6- mercaptopurine, cytotoxic cancer chemotherapeutic agents, bradykinin (BK2) antagonists such as FK-3657, TP receptor antagonists such as seratrodast, neurokinin antagonists (NK1/NK2), VLA- 4 antagonists such as those described in US 5,510,332, WO97/03094, WO97/02289, WO96/40781, WO96/22966, WO96/20216, WO96/01644, WO96/06108, WO95/15973 and
20 WO96/31206. In addition, the invention encompasses a method of treating prostaglandin D2 mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of formula I, optionally co-administered with one or more of such ingredients as listed immediately above.
25 METHODS OF SYNTHESIS
Compounds of Formula I of the present invention can be prepared according to the synthetic routes outlined in the following scheme(s) and by following the methods described herein.
In Scheme I, the amine I can be alkylated, for example with an alkyl iodide in the
30 presence of a base such as NaH, to provide 2. Alternatively I can be subject to reductive animation conditions to give 2. Compounds I and 2 can be converted to the corresponding amide using HATU as coupling agent with an carboxylic acid or acylated with an acyl chloride, and the resulting product can be hydrolyzed to provide a compound of formula I using well known processes.
35 MCC-BRE-00003
Scheme I
Figure imgf000014_0001
Compounds of formula I in which Y is other than methylene may be prepared according to the general procedures outlined in WO2007019675, the relevant portions are hereby 5 incorporated by reference.
The following examples are provided to illustrate the invention only, and are not to be construed as limiting the scope thereof in any manner.
PREPARATION OF INTERMEDIATES 10 Propyl ([7R]-7-amino-6,7,8,9-tetrahvdropyrido[l,2-αlindol-10-yl)acetate
Step 1: ethyl 3-(6-oxo- 1 -phenyl-1 AS.ό-tetrahvdropyridazin-B-vDpropanoate
In a three neck flask equipped with a Dean-Stark trap, phenylhydrazine hydrochloride and diethyl 4-oxoheptanedioate (1 equiv.) were combined in toluene (1.15 M).
The suspension was stirred 48 h at reflux. The reaction mixture was cooled to rt and 15 concentrated under vacuum to afford the desired material as a brown oil which was used as such in the next step.
Step 2: propyl 3 - [3 -(2-oxo-2-propoxyethyl)- 1 //-mdol-2-yl]propanoate
Methanesulfonic acid (1.15 equiv.) was added to a stirred solution of ethyl 3-(6- oxo-l-phenyl-l,4,5,6-tetrahydropyridazin-3-yl)propanoate from Step 1 in n-propanol (1.1 M). MCC-BRE-00003
The mixture was stirred overnight at 800C. The mixture was cooled to room temperature and neutralized with aqueous IN NaOH (1 equiv.). Final mixture was concentrated under vacuum, diluted with toluene and concentrated again. The residue was purified by column chromatography on silica gel using automatized gradiant pump system CombiFlashRF (Teledyne 5 ISCO) eluting with ethyl acetate/hexane (0: 100 to 60:40) to give the title compound (79%) as a brown oil. Step 3 : 3-[3-(2-oxo-2-propoxyethyl)-lH-indol-2-yl"|propanoic acid
Aqueous 8N KOΗ (1.05 equiv.) was added to a stirred solution of propyl 3-[3-(2- oxo-2-propoxyethyl)-lH-indol-2-yl]propanoate from Step 2 in rø-propanol (0.5 M). The mixture
10 was stirred at 5O0C for 4 h. The reaction mixture was cooled to rt, quenched with acetic acid (1.2 equiv.) and concentrated. The residue was purified on a pad of silica gel using CH2Cl2, then CH2Cl2 / EtOAc (9/1) and finally CH2Cl2/Et0Ac/Me0H (88/10/2) to afford after evaporation of the volatiles, the desired material (68%) as yellow oil. Step 4: propyl |~2-(4-diazo-3-oxobutyl)-lH-indol-3-yl]acetate
15 N-methylmorpholine (1.1 equiv.) was added dropwise over Ih to a stirred, 0 0C mixture of 3-[3-(2-oxo-2-propoxyethyl)-lH-indol-2-yl]propanoic acid from Step 3 and ethyl chloroformate (1.11 equiv.) in TΗF (0.4 M). The reaction temperature was closely monitored during the addition and was not allowed to go over +20C. The mixture was stirred at 00C an additional 30min. A white precipitate formed rapidly. Diazomethane (0.3 M in Et2O, 1.8 equiv.)
20 was added and the final mixture was stirred for 2h at O0C. The mixture was filtered and the supernatant was concentrated under vacuum (with AcOH put in the vacuum trap to quench excess diazomethane). The residue was purified by column chromatography on silica gel using automatized gradiant pump system CombiFlashRF (Teledyne ISCO) eluting with EtOAc/Ηexane( 10:90 to 60:40) to give the title compound (63%) as a yellow solid.
25 Step 5: propyl (7-oxo-6,7,8,9-tetrahydropyrido[L2-a1indol-10-yl)acetate
Rhodium (II) octanoate dimmer (0.1 equiv.) was added to a CH2Cl2 solution (0.02 M) of propyl [2-(4-diazo-3-oxobutyl)-lH-indol-3-yl]acetate from Step 4. The reaction mixture was stirred overnight at rt and then concentrated. The residue was purified by column chromatography on silica gel using automatized gradiant pump system CombiFlashRF (Teledyne
30 ISCO) eluting with EtOAc/Ηexane (2:98 to 10:90) to give the title compound (64%) as a yellow solid. Step 6: propyl f [7Rl-7-amino-6 J,8,9-tetrahydropyrido[L2-α|indol-l O-yl)acetate
Sodium phosphate, dibasic (3.8 equiv.) and sodium formate (266 equiv.) were added to a solution of D-alanine (38 equiv.) in water. The pΗ was measured as 7.6. NAD (0.04
35 equiv.), Pyridoxal-5-phosphate (0.11 equiv.), Lactate dehydrogenase (LDΗ) (1 equiv.), Formate dehydrogenase (FDΗ) (1 equiv.), and Amine-Transaminase ATAl 17 (1 equiv.) were added under stirring and slowly dissolved. The measured pΗ was 7.3. The mixture was aged at 22 0C for Ih. The flask was flushed with nitrogen and propyl (7-oxo-6,7,8,9-tetrahydropyrido[l,2-α]- MCC-BRE-00003
indol-10-yl)acetate from Step 5 was added as a DMSO (0.06 M) solution. The reaction was adjusted to pH 7.2 and aged at 30 0C overnight under nitrogen atmosphere. Upon completion of the reaction as determined by HPLC, the pH of the reaction was adjusted to pH 4.0 with 6N HCl and Celite (20 g per L) was added. After stirring for lhr the reaction was filtered through a Celite 5 bed and the filter cake was washed twice with 0. IN HCl. The combined aqueous filtrate was extracted with 1 volume of MTBE. The organic layer did not contain amine and was discarded. The aqueous layer was diluted with an equal volume of MTBE and the pH of the mixture was adjusted to pH 9.5 using 5N NaOH. The two phases were separated and the aqueous layer was extracted with MTBE. The spent aqueous layer had no detectable amine and was discarded. The 10 combined organic layers were washed with dilute sodium carbonate and dried over Na2SO4.
Evaporation of the volatiles afforded the crude title compound (80%). The ee was determined as 99% by SFC assay.
Preparation of Intermediates - General Procedure
15 Compounds of types 1 and 2 can be prepared according to the procedure outlined in Schemes II and III. In Scheme II aspartic acid dimethyl ester IH is treated with sulfonyl chloride II-ii in THF in the presence of triethylamine to afford the sulfonyl amide diester II-iii. Reduction of the diester II-iii with e.g., sodium borohydride provides the diol II-iv, which, under Mitsunobu conditions, provides the aziridine U1V. The primary alcohol of II-v can be protected
20 with a silyl ether group to give protected aziridine II-vi.
Scheme II
Figure imgf000016_0001
TBDMSi
Et3N/imidazole/THF
Figure imgf000016_0002
l-vi
25 In Scheme III the indole III-i is condensed with the aziridine II-vi in the presence of sodium hydride to provide III-ii. The silyl group is removed with TBAF followed by oxidation MCC-BRE-00003
with DMSO or a Dess-Martin reagent to afford the corresponding aldehyde which, when heated in toluene in the presence PPTS, provides the corresponding cyclized compound III-iv Hydrogenation of compound III-iv gives the sulfonamide III-v Sulfonamide III-v, when treated with magnesium in methanol (See Monika Fitz Tetrahedron Asymmetry 2005, 16, 3690 for examples of sulfonamide cleavage), provides the amine III-vi
Scheme III
Figure imgf000017_0001
R3 = a R3 group other than H such as methyl R = lower alkyl (methyl, ethyl, propyl, etc )
10
Compounds of formula I can be prepared according to the procedures described in the Schemes and Examples herein, using appropriate materials and are further exemplified by the following specific examples The compounds exemplified are not, however, to be construed as limiting the scope of the invention in any manner The examples further illustrate details for the
15 preparation of the compounds of the present invention Those skilled in the art will readily understand that known variations of protecting groups, of reagents, as well as of the conditions and processes of the following preparative procedures, can be used to prepare these compounds MCC-BRE-00003
It is also understood that whenever a chemical reagent is not commercially available, such a chemical reagent can be readily prepared by those skilled in the art by either following or adapting known methods described in the literature. All temperatures are degrees Celsius unless otherwise noted. Mass spectra (MS) were measured either by electrospray ion-mass 5 spectroscopy (ESMS) or by atmospheric pressure chemical ionization mass spectroscopy (APCI).
EXAMPLE 1
{(7J?)-7-[[2-(4-Fluorophenyl)propanoyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-o]indol-10- yl} acetic acid
Figure imgf000018_0001
Step 1 : Propyl r(7i?)-7-(methylaminoV6.7,8.9-tetrahvdropyridoπ.2-α1indol-10-yllacetate
Propyl [(7i?)-7-amino-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate (2.5 g) and TEA (1.4 mL) were dissolved in 87 niL MeOH. Boc2O (2.1 g) was added in 10 mL MeOH, and the mixture was stirred for 2 h. The solvent was removed and propyl {(7J?)-7-[(/ert-butoxy-
15 carbonyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetate was purified on silica gel (ethyl acetate/hexanes). Propyl {(7i?)-7-[(/ert-butoxycarbonyl)amino]-6,7,8,9-tetrahydro- pyrido[l,2-α]indol-10-yl}acetate (3.15 g) was dissolved in DMF (81 mL). The mixture was cooled in an ice bath and MeI (3.47 g) was added followed by NaH (342 mg, 60% w/w in mineral oil). The ice bath was removed after 0.5 h, and the mixture was stirred for 1 h at RT. The
20 reaction was quenched with 1/2 (sat.) aqueous ammonium chloride. Work up consisted of extraction of the aqueous layer with ether (2 x). The combined organic fractions were washed with water and brine, then dried (MgSO4). The solvent was evaporated under reduced pressure and propyl {(7i?)-7-[(/er/-butoxycarbonyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l ,2-α]indol- 10-yl}acetate was purified on silica gel (ethyl acetate/hexanes). {(7/?)-7-[(terf-butoxycarbonyl)-
25 (methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-(3]indol-10-yl}acetate and anisole (2.2 g) were dissolved in 66 mL DCM. 66 mL of TFA was added and the mixture was stirred for 1 h. The mixture was then stripped several times with toluene. Work up consisted of extraction with dichloromethane (3 x) from aqueous sodium carbonate. The combined organic fractions were washed with brine and dried (MgSO 4 ). The solvent was evaporated under reduced pressure and
30 propyl [(7i?)-7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate was obtained after purification on silica gel. (MeOH/DCM). MCC-BRE-00003
Step 2: Preparation of 2-(4-fluorophenyl)propanoic acid.
Methyl (4-fluorophenyl)acetate (0.5 g) was dissolved in DMF (81 niL). The mixture was cooled in an ice bath and NaH (131 mg, 60% w/w in mineral oil) was added. The 5 mixture was stirred for 1 h at RT and again cooled in an ice bath before the addition of MeI (633 mg). The mixture was warmed to RT and, the reaction was quenched with 1/2 (sat.) aqueous ammonium chloride. Work up consisted of extraction of the aqueous layer with ether (2 x). The combined organic fractions were washed with water and brine, then dried (MgSCU). The solvent was evaporated under reduced pressure and methyl 2-(4-fluorophenyl)propanoate was purified on
10 silica gel (ethyl acetate/hexanes). Methyl 2-(4-fluorophenyl)propanoate (420 mg) was dissolved in 12 mL THF and 6 mL MeOH. 6 mL of KOH (2M) was added and the mixture was stirred for 2 h at RT. Water was added and the organic solvents were removed. The base was quenched with icy hydrochloric acid (IN), DCM was added and the phases separated with a phase separator. The solvent was removed under reduced pressure to provide the title compound.
15 Step 3: (Method A)
2-(4-Fluorophenyl)propanoic acid. (33 mg) and HATU (76 mg) were dissolved in DMF (1.3 mL). DIPEA (87 μL, 0.315 mmol) was added and the mixture was stirred for 1 min before the addition of propyl [(7i?)-7-(methylamino)-6,7,8,9-tetrahydropyrido[l ,2-α]indol-10- yl]acetate (50 mg) in 1 mL DMF. The reaction mixture was stirred for 2 h. The solvent was
20 removed under vacuum and the residue was purified on silica gel (ethyl acetate/hexanes). The resulting diastereoisomers were separated on a Chiralpak AD column (20% iPrOH/Hexanes, 0.25% HCOOH). The propyl esters were hydrolysed to their corresponding acids using a procedure analogous to the one described in Step 2. MS (+ESI) m/z: 409.
25 EXAMPLE 2
{(7Λ)-7-[[(4-fluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-fl]indol-10- yl} acetic acid
Figure imgf000019_0001
(Method B)
30 Propyl [(7R)-7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2-a]indol-10-yl]acetate
(Example 1) (20.0 mg) was dissolved in DCM (2.0 mL) then DMAP (0.449 mg), (4-fluoro- phenyl)acetyl chloride (16.0 μL) and triethylamine (10.24 μL) were added to the solution under MCC-BRE-00003
nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2 h then quenched with ^(sat.) aqueous ammonium chloride. DCM (4.0 mL) was added and the two phases were separated by using a phase separator. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel (ethyl acetate/hexanes). The 5 resultant material was dissolved in THF (2.0 mL) and MeOH (1.0 mL) then sodium hydroxide (1.32 mL) was added to the solution. The reaction was stirred for 2.5 h at room temperature and then quenched with HCl (IN). DCM was added and the two phases were separated with a phase separator. The organic layers were evaporated under reduced pressure to provide the title compound. MS (+ESI) m/z: 395.2. 10
EXAMPLE 3
((7i?)-7-{(4-fluorobenzyl)[(4-fluorophenyl)acetyl]amino}-6,7,8,9-tetrahydropyrido[l,2-fl]indol- 10-yl)acetic acid
Figure imgf000020_0001
15 4-Fluorobenzaldehyde (43.0 μL) was dissolved in MeOH (3.0 mL) and then propyl [(7i?)-7-amino-6,7,8,9-tetrahydropyrido[l ,2-α]indol-10-yl]acetate (231 mg) in MeOH (2.0 mL), sodium cyanoborohydride (50.6 mg) and acetic acid (92.0 μL) were added. The reaction mixture was stirred for overnight at room temperature then quenched with NaOH (IN). The aqueous phase was extracted with EtOAc. The organic layers were washed with brine, dried over
20 magnesium sulfate, filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (ethyl acetate/hexanes). The resulting benzylamine (48.0 mg) was dissolved in DCM (2.0 mL) and then DMAP (0.743 mg), (4- fluorophenyl)acetyl chloride (32.8 mg) and triethylamine (17.0 μL) were added to the solution under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 2 h then
25 quenched with ^(sat.) aqueous ammonium chloride. DCM (4.0 mL) was added and the two phases were separated by using a phase separator. The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel (ethyl acetate/hexanes) to give the title compound as a yellow oil. The resultant material was dissolved in THF (4.0 mL) and MeOH (2.0 mL) then NaOH (0.283 mL, IN) were added to the solution.
30 The reaction was stirred for 2.5 h at room temperature and then quenched with HCl (IN). DCM MCC-BRE-00003
was added and the two phases were separated with a phase separator. The organic layers were evaporated under reduced pressure to provide the title compound.JMS (+ESI) m/z: 489.
EXAMPLE 4
[(7i?)-7-({[l-(4-fluorophenyl)cyclopentyl]carbonyl}amino)-6,7,8,9-tetrahydropyrido[l ,2-α]indol- 10-yl] acetic acid
Figure imgf000021_0001
The title compound was prepared using analogous procedures described in Example 1 (Method A) from l-(4-fluorophenyl)cyclopentanecarboxylic acid and propyl [(7i?)-7- 10 amino-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate . MS (+ESI) m/z: 435.
EXAMPLE 5
{(7i?)-7-[{[l-(4-fluorophenyl)cyclopentyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido [ 1 ,2-a] indol- 10-yl } acetic acid
Figure imgf000021_0002
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 1 -(4-fluorophenyl)cyclopentanecarboxylic acid and propyl [(7i?)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 449.
20 EXAMPLE 6
{(7i?)-7-[[2-(4-fluorophenyl)-2-methylpropanoyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2- a] indol- 10-yl} acetic acid MCC-BRE-00003
Figure imgf000022_0001
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 2-(4-fluorophenyl)-2-methylpropanoic acid and propyl [(7R)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 423.
EXAMPLE 7
{(7i?)-7-[[(2,4-difluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10- yl} acetic acid
Figure imgf000022_0002
10 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from (2,4-difluorophenyl)acetic acid and propyl [(7^)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 413.
EXAMPLE 8
15 {(7i?)-7-[[(2-chloro-4-fluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l ,2-α]indol- 10-yl} acetic acid
Figure imgf000022_0003
MCC-BRE-00003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from (2-chloro-4-fluorophenyl)acetic acid and propyl [(7R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 429.
EXAMPLE 9
{ (IR)-I- [ [(3 -chloro-4-fluorophenyl)acetyl] (methyl)amino] -6, 7, 8 ,9-tetrahydropyrido [ 1 ,2-a] indol- 10-yl} acetic acid
Figure imgf000023_0001
The title compound was prepared using analogous procedures described in 10 Example 1 (Method A) from (3-chloro-4-fluorophenyl)acetic acid and propyl [(7R)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 429.
EXAMPLE 10
{(7Λ)-7-[{[4-fluoro-2-(trifluoromethyl)phenyl]acetyl}(methyl)amino]-6,7,8,9-tetrahydro- 15 pyrido[l,2-α]indol-10-yl}acetic acid
Figure imgf000023_0002
The title compound was prepared using analogous procedures described in Example 1 (Method A) from [4-fluoro-2-(trifluoromethyl)phenyl]acetic acid and propyl [(7i?)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 463.
20
EXAMPLE I l
{(7i?)-7-[{[4-fluoro-3-(trifluoromethyl)phenyl]acetyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido[l,2-α]indol-10-yl}acetic acid MCC-BRE-00003
Figure imgf000024_0001
The title compound was prepared using analogous procedures described in Example 1 (Method A) from [4-fluoro-3-(trifluoromethyl)phenyl]acetic acid and propyl [(7i?)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 463.
EXAMPLE 12
{(7i?)-7-[(2,3-dihydro-lH-inden-l-ylcarbonyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]- indol-10-yl} acetic acid
Figure imgf000024_0002
10 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from indane-1-carboxylic acid and propyl [(7i?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 403.
EXAMPLE 13
15 { (IR)-I- [ [4-(difluoromethyl)-3 -iodobenzoyl](methyl)amino] -6,7,8,9-tetrahydropyrido [ 1 ,2-a] - indol-10-yl} acetic acid
Figure imgf000024_0003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 4-(difluoromethyl)-3-iodobenzoic acid and propyl [(7i?)-7- 20 (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 539. MCC-BRE-00003
EXAMPLE 14
{(7i?)-7-[[(2-(2-bromo-4-fluorophenyl)propanoyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2- α]indol-10-yl} acetic acid
Figure imgf000025_0001
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 2-(2-bromo-4-fiuorophenyl)propanoic acid and propyl [(7R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 487.
10 EXAMPLE 15
{(7i?)-7-[(4-fluorobenzoyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid
Figure imgf000025_0002
The title compound was prepared using analogous procedures described in
15 Example 2 (Method B) from 4-fluorobenzoyl chloride and propyl [(77?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2-fl]indol-10-yl]acetate. MS (+ESI) m/z: 381.
EXAMPLE 16
{(7i?)-7-[(cyclopentylcarbonyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic 20 acid
Figure imgf000025_0003
MCC-BRE-00003
The title compound was prepared using analogous procedures described in Example 2 (Method B) from cyclopentanecarboxylic acid and propyl [(7i?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 355.
5 EXAMPLE 17
{(7i?)-7-[(cyclopropylcarbonyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l ,2-α]indol-10-yl}acetic acid
Figure imgf000026_0001
The title compound was prepared using analogous procedures described in
10 Example 2 (Method B) from cyclopropanecarboxylic acid and propyl [(7/?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 327.
EXAMPLE 18
((7i?)-7-{methyl[(5-methylisoxazol-3-yl)carbonyl]amino}-6,7,8,9-tetrahydropyrido[l,2-α]indol- 15 10-yl)acetic acid
Figure imgf000026_0002
The title compound was prepared using analogous procedures described in Example 2 (Method B) from 5-methylisoxazole-3-carbonyl chloride and propyl [(7R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 368. 20
EXAMPLE 19
(IR)-I- [[(4-chlorophenyl)acetyl] (methyl)amino] -6,7,8,9-tetrahydropyrido [ 1 ,2-a] indol- 10-yl } - acetic acid MCC-BRE-00003
Figure imgf000027_0001
The title compound was prepared using analogous procedures described in Example 2 (Method B) from (4-chlorophenyl)acetyl chloride and propyl [(7i?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-fl]indol-10-yl]acetate. MS (+ESI) m/z: 41 1.
EXAMPLE 20
{(7i?)-7-[{[l-(4-chlorophenyl)cyclopentyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido [ 1 ,2-a] indol- 10-yl } acetic acid
Figure imgf000027_0002
10 The title compound was prepared using analogous procedures described in
Example 2 (Method B) from l-(4-chlorophenyl)cyclopentanecarbonyl chloride and propyl [(7R)- 7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 487.
EXAMPLE 21
15 {(7Λ)-7-[[(4-methoxyphenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}- acetic acid
Figure imgf000027_0003
The title compound was prepared using analogous procedures described in Example 2 (Method B) from (4-methoxyphenyl)acetyl chloride and propyl [(7R)-7- 20 (methylamino)-6,7,8,9-tetrahydropyrido[l,2-<3]indol-10-yl]acetate. MS (+ESI) m/z: 407. MCC-BRE-00003
EXAMPLE 22 {(7i?)-7-[methyl(phenoxyacetyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid
Figure imgf000028_0001
The title compound was prepared using analogous procedures described in
5 Example 2 (Method B) from phenoxyacetyl chloride and propyl [(7J?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 393.
EXAMPLE 23 {(7i?)-7-[methyl(phenylacetyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid
Figure imgf000028_0002
The title compound was prepared using analogous procedures described in Example 2 (Method B) from phenylacetyl chloride and propyl [(7i?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 377.
15 EXAMPLE 24
{(7J/?)-7-[methyl(2-naphthoyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid
Figure imgf000028_0003
The title compound was prepared using analogous procedures described in Example 2 (Method B) from 2-naphthoyl chloride and propyl [(7i?)-7-(methylamino)-6, 7,8,9- 20 tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 413. MCC-BRE-00003
EXAMPLE 25
{(7i?)-7-[[(3,4-difluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-o]indol-10- yl} acetic acid
Figure imgf000029_0001
The title compound was prepared using analogous procedures described in Example 2 (Method B) from (3,4-difluorophenyl)acetyl chloride and propyl [(I R)-I - (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]mdol-10-yl]acetate. MS (+ESI) m/z: 413.
10 EXAMPLE 26
{(7i?)-7-[(2,2-dimethyl-3-phenylpropanoyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol- 10-yl} acetic acid
Figure imgf000029_0002
The title compound was prepared using analogous procedures described in 15 Example 2 (Method B) from 2,2-dimethyl-3-phenylpropanoyl chloride and propyl [(7R)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 419.
EXAMPLE 27
[(7i?)-7-(methyl{[4-(trifluoromethyl)phenyl]acetyl}amino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-
20 10-yl]acetic acid
Figure imgf000029_0003
MCC-BRE-00003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from [4-(trifluoromethyl)phenyl]acetic acid and propyl [(7i?)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 445.
5 EXAMPLE 28
{(7i?)-7-[methyl(l-naphthylacetyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid
Figure imgf000030_0001
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 1-naphthylacetic acid and propyl [(7/?)-7-(methylamino)-6,7,8,9- 10 tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 427
EXAMPLE 29
{(7i?)-7-[methyl(3-phenylpropanoyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid
Figure imgf000030_0002
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 3-phenylpropanoic acid, and propyl [(7i?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 391.
20 EXAMPLE 30
((7J?)-7-{methyl[2-phenylpropanoyl]amino}-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl)acetic acid MCC-BRE-00003
Figure imgf000031_0001
The title compound was prepared using analogous procedures described in Example 1 (Method A) from hydratropic acid and propyl [(7i?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 391.
EXAMPLE 31
{(7i?)-7-[{[l-(4-fluorophenyl)cyclopropyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido [ 1 ,2-a] indol- 10-yl } acetic acid
Figure imgf000031_0002
10 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from 1 -(4-fluorophenyl)cyclopropanecarboxylic acid and propyl [(7i?)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-(3]indol-10-yl]acetate. MS (+ESI) m/z: 321.
EXAMPLE 32
15 { {1 R)-I- [ { [ 1 -(4-fluorophenyl)cyclobutyl]carbonyl} (methyl)amino] -6,7,8,9-tetrahydropyrido [1,2- a] indol- 10-yl } acetic acid
Figure imgf000031_0003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 1 -(4-fluorophenyl)cyclobutanecarboxylic acid and propyl [(JR)-I- 20 (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 435. MCC-BRE-00003
EXAMPLE 33
{(7i?)-7-[[2-(4-fluorophenyl)-2-piperidin-l-ylacetyl](methyl)amino]-6,7,8,9-tetrahydro- pyrido [ 1 ,2-a] indol- 10-yl } acetic acid
Figure imgf000032_0001
5 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from (4-fluorophenyl)(piperidin-l-yl)acetic acid and propyl [(7 R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 478.
EXAMPLE 34
10 {(7i?)-7-[[(2-bromo-4-fluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol- 10-yl} acetic acid
Figure imgf000032_0002
The title compound was prepared using analogous procedures described in Example 1 (Method A) from (2-bromo-4-fluorophenyl)acetic acid and propyl [(7i?)-7- 15 (methylamino)-6,7,8,9-tetrahydropyrido[l ,2-α]indol-l O-yl]acetate. MS (+ESI) m/z: 473.
EXAMPLE 35
{(7J?)-7-[{[l-(4-fluorophenyl)-2,2-dimethylcyclopropyl]carbonyl}(methyl)amino]-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl}acetic acid MCC-BRE-00003
Figure imgf000033_0001
The title compound was prepared using analogous procedures described in Example 1 (Method B) l-(4-fluorophenyl)-2,2-dimethylcyclopropanecarboxylic acid and propyl [(7J?)-7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2-fl]indol-10-yl]acetate. MS (+ESI) m/z: 449.
EXAMPLE 36
{(7i?)-7-[[-2-methoxy-2-phenylacetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10- yl} acetic acid
Figure imgf000033_0002
10 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from methoxy(phenyl)acetic acid and propyl [(7i?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 407.
EXAMPLE 37
15 {(7J?)-7-[Methyl-(2-thiophen-2-yl-acetyl)-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10-yl}- acetic acid
Figure imgf000033_0003
MCC-BRE-00003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from thiophen-2-yl acetic acid and propyl [(7/f)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 383.
5 EXAMPLE 38
{ {1 R)-I- [Methyl-(2-thiophen-3-yl-acetyl)-amino] -6,7,8,9-tetrahydro-pyrido [ 1 ,2-a]indol- 10-yl } - acetic acid
Figure imgf000034_0001
The title compound was prepared using analogous procedures described in 10 Example 1 (Method A) from thiophen-3-yl acetic acid and propyl [(7i?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 383.
EXAMPLE 39
((7i?)-7-{[2,2-Bis-(4-fluoro-phenyl)-acetyl]-methyl-amino}-6,7,8,9-tetrahydro-pyrido[l,2- 15 a]indol-10-yl)-acetic acid
Figure imgf000034_0002
The title compound was prepared using analogous procedures described in Example 1 (Method A) from bis(4-fluorophenyl)acetic acid and propyl [(77?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 489.
20 MCC-BRE-00003
EXAMPLE 40 {(7/?)-7-[(diphenylacetyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l ,2-α]indol-l O-yl}acetic acid
Figure imgf000035_0001
The title compound was prepared using analogous procedures described in
5 Example 2 (Method B) from diphenylacetyl chloride and propyl [(7i?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 453.
EXAMPLE 41 {(7i?)-7-[(diphenylacetyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid
Figure imgf000035_0002
The title compound was prepared using analogous procedures described in Example 2 (Method B) from 2-phenylbutanoyl chloride and propyl [(7i?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 405. MCC-BRE-00003
EXAMPLE 42
((7J?)-7-{Methyl-[2-(2-methyl-thiazol-4-yl)-acetyl]-amino}-6,7,8,9-tetrahydro-pyrido[l,2- a]indol-10-yl)-acetic acid
Figure imgf000036_0001
5 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from (2-methyl-l,3-thiazol-4-yl)acetic acid and propyl [(7R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-fl]indol-10-yl]acetate. MS (+ESI) m/z: 398.
EXAMPLE 43
10 ((7i?)-7-{[2-(3,5-Dimethyl-isoxazol-4-yl)-acetyl]-methyl-amino}-6,7,8,9-tetrahydro-pyrido[l,2- a]indol-10-yl)-acetic acid
Figure imgf000036_0002
The title compound was prepared using analogous procedures described in Example 1 (Method A) from (3,5-dimethylisoxazol-4-yl)acetic acid and propyl [(7R)-7- 15 (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 396.
EXAMPLE 44
{{1 R)-I- { [2-Ethyl-2-(4-fluoro-phenyl)-butyryl] -methyl-amino } -6,7,8,9-tetrahydro-pyrido [ 1 ,2- a]indol-10-yl)-acetic acid MCC-BRE-00003
Figure imgf000037_0001
The title compound was prepared using analogous procedures described in Example 2 (Method B) from 2-ethyl-2-(4-fluorophenyl)butanoyl chloride and propyl [(7R)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 451.
EXAMPLE 45
((7i?)-7-{[3-Cyclopropyl-2-(4-fluoro-phenyl)-propionyl]-methyl-amino}-6,7,8,9-tetrahydro- pyrido [ 1 ,2-a] indol- 10-yl)-acetic acid
Figure imgf000037_0002
10 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from 3-cyclopropyl-2-(4-fluorophenyl)propanoic acid and propyl [(I R)- 7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 449.
EXAMPLE 46
15 [(7R)-7-{ [(2i?)-2-hydroxy-2-phenylpropanoyl](methyl)amino} -6,7,8,9-tetrahydropyrido [1 ,2- a] indol- 10-yl] acetic acid
Figure imgf000037_0003
MCC-BRE-00003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from (2i?)-2-hydroxy-2-phenylpropanoic acid and propyl [(7i?)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 407.
5 EXAMPLE 47
[(7i?)-7-{[(25)-2-hydroxy-2-phenylpropanoyl](methyl)amino}-6,7,8,9-tetrahydropyrido[l,2-α]- indol-10-yl]acetic acid
Figure imgf000038_0001
The title compound was prepared using analogous procedures described in 10 Example 1 (Method A) from (25)-2-hydroxy-2-phenylpropanoic acid and propyl [(7R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 407.
EXAMPLE 48
((7^)-7-{Ethyl-[l-(4-fluoro-phenyl)-cyclopropanecarbonyl]-amino}-6,7,8,9-tetrahydro- 15 pyrido [ 1 ,2-a] indol- 10-yl)-acetic acid
Figure imgf000038_0002
Step 1 : propyl [(7/?)-7-(ethylaminoV6.7.8.9-tetrahydropyrido[l .2-αlindol-l O-yl]acetate This compound was achieved according to the general procedures outlined in
Scheme III.
20 Step 2: ((7/?)-7-(Ethyl-[l-(4-fluoro-phenylVcvclopropanecarbonyl]-aminoj-6J,8,9- tetrahydro-pyrido [ 1 ,2-a]indol- 10-ylV acetic acid
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 1 -(4-fluorophenyl)cyclopropanecarboxylic acid and propyl [(7i?)-7- (ethylamino)-6,7,8,9-tetrahydropyrido[l,2-fl]indol-10-yl]acetate. MS (+ESI) m/z: 435.
25
EXAMPLE 49 MCC-BRE-00003
[(7i?)-7-(methyl{[2-(pyπdin-4-yl)cyclopropyl]carbonyl}amino)-6,7,8,9-tetrahydropyπdo[l,2- α]indol-10-yl] acetic acid
Figure imgf000039_0001
The title compound was prepared using analogous procedures descπbed in Example 1 (Method A) from 2-(pyridm-4-yl)cyclopropanecarboxylic acid and propyl [(7R)-7- (methylamino)-6,7,8,9-tetrahydropyπdo[l,2-α]indol-10-yl]acetate MS (+ESI) m/z 404
EXAMPLE 50
{(7i?)-7-[(bicyclo[4 2 0]octa-l,3,5-trien-7-ylcarbonyl)(methyl)amino]-6,7,8,9- 10 tetrahydropyπdo[l,2-α]indo
Figure imgf000039_0002
The title compound was prepared using analogous procedures descπbed in Example 1 (Method A) from bicyclo[4 2.0]octa-l,3,5-triene-7-carboxylic acid and propyl [(7R)- 7-(methylamino)-6,7,8,9-tetrahydropyπdo[l,2-α]mdol-10-yl]acetate MS (+ESI) m/z- 389
15
EXAMPLE 51
{(7Λ)-7-[(imidazo[l,2-α]pyridin-3-ylacetyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol- 10-yl} acetic acid
Figure imgf000039_0003
MCC-BRE-00003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from imidazo[l,2-a]pyridin-3-ylacetic acid and propyl [(7 R)-I- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 417.
5 EXAMPLE 52
[(75)-7- { [(4-fluorophenyl)acetyl] (methyl)amino } -6,7,8,9-tetrahydropyrido [ 1 ,2-α]indol- 10- yl]acetic acid
Figure imgf000040_0001
Step 1 : methyl 17-ilY4-fluorophenvDsulfonyll (methvDamino) -6.7.8.9-
10 tetrahydropyrido [ 1 ,2-al indol- 10-yl]acetate
This compound may be prepared according to the general procedures outlined in WO2007019675. Step 2: methyl r(7^-7-{ r(4-fluorophenvnsulfonyl¥methyl)aminol-6.7.8.9- tetrahvdropyrido [ 1 ,2-a] indol- 10-yl] acetate 15 The methyl [7-{[(4-fluorophenyl)sulfonyl](methyl)amino]-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl}acetate was resolved by chiral HPLC using a ChiralpakAD column and eluting with a mixture of 20%EtOH/20%z'PrOH/60%Hex to afford equal amounts of methyl [(7S)-7-{[(4-fluorophenyl)sulfonyl] (methyl)amino} -6,7,8,9-tetrahydropyrido[l,2- α]indol-10-yl]acetate (retention time = 5.90 min (>99%ee)) and methyl [(7i?)-7-{[(4- 20 fluorophenyl)sulfonyl](methyl)amino}-6,7,8,9-tetrahydrop3τido[l,2-α]indol-10-yl]acetate (retention time = 13.31 min (>99%ee))
Step 3: methyl [(7y>-7-(methylamino)-6.7,8,9-tetrahydropyridori.2-fl1indol-10-yl]acetate
The deprotection of the amine was achieved according to the general procedures outlined in Scheme III (See Monika Fitz Tetrahedron Asymmetry 2005, 16, 3690 for examples of 25 sulfonamide cleavage).
Step 4: r(7^)-7-ir(4-fluorophenyl)acetyll(methyl)amino}-6.7.8.9-tetrahvdropyridori.2- a] indol- 10-yl] acetic acid
The title compound was prepared using analogous procedures described in Example 1 (Method A) from (4-fluorophenyl)acetic acid and methyl [(75)-7-(methylamino)- 30 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 395. MCC-BRE-00003
EXAMPLE 53
((1R)-I- { [4-(4-Fluoro-phenyl)-tetrahydro-pyran-4-carbonyl]-methyl-amino } -6,7,8,9-tetrahydro- pyrido [ 1 ,2-a] indol- 10-yl)-acetic acid
Figure imgf000041_0001
5 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from 4-(4-fluorophenyl)tetrahydro-2H-pyran-4-carboxylic acid and propyl [(7i?)-7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 465.
10 EXAMPLE 54
{(7R)-7-[(2-Methoxy-2-phenyl-acetyl)-methyl-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10- yl} -acetic acid
Figure imgf000041_0002
The title compound was prepared using analogous procedures described in 15 Example 1 (Method A) from methoxy(phenyl)acetic acid and propyl [(7/?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 407.
EXAMPLE 55
[(7i?)-7-{methyl[(2i? or 25)-2-phenylpropanoyl]amino}-6,7,8,9-tetrahydropyrido[l,2-a]indol-10- 20 yl] acetic acid MCC-BRE-00003
Figure imgf000042_0001
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 2-phenylpropanoic acid and propyl [(7i?)-7-(methylammo)-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl]acetate. The separation of the resulting diastereoisomers was performed at the ester stage on chiral HPLC using a 4.6x250mm Chiralcel OD column eluting with 30% iPrOH, 69.75% Hexanes and 0.25% HCOOH at lmL/min and 254nm. Retention times = 5.0 and 8.1min. The two resulting esters were hydrolyzed separately to afford EXAMPLE 55.1 and 55.2 respectively. MS (+ESI) m/z: 391.
10 EXAMPLE 56
{ {1 R)-I- [MethyH 1 ,2,3 ,4-tetrahydro-naphthalene- 1 -carbonyl)-amino] -6,7,8,9-tetrahydro- pyrido[l,2-a]indol-10-yl} -acetic acid
Figure imgf000042_0002
The title compound was prepared using analogous procedures described in
15 Example 1 (Method A) from 1,2,3,4-tetrahydronaphthalene-l-carboxylic acid and propyl [(7R)- 7-(methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 417.
EXAMPLE 57
((7i?)-7-{[2-(4-Dimethylamino-phenyl)-acetyl]-methyl-amino}-6,7,8,9-tetrahydro-pyrido[l,2-
20 a]indol-10-yl)-acetic acid MCC-BRE-00003
Figure imgf000043_0001
The title compound was prepared using analogous procedures described in Example 1 (Method A) from [4-(dimethylamino)phenyl] acetic acid and propyl [(7J?)-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 420.
EXAMPLE 58
{(7Λ)-7-[(2-Cyclopentyl-acetyl)-methyl-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10-yl}- acetic acid
Figure imgf000043_0002
10 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from cyclopentylacetic acid and propyl [(7i?)-7-(methylamino)-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 369.
EXAMPLE 59
15 ((7J?)-7-{Methyl-[3-(piperidine-l-sulfonyl)-benzoyl]-amino}-6,7,8,9-tetrahydro-pyrido[l,2- a]indol-10-yl)-acetic acid
Figure imgf000043_0003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 3-(piperidin-l-ylsulfonyl)benzoic acid and propyl [{1 R)-I- 20 (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 510. MCC-BRE-00003
EXAMPLE 60
{(7Λ)-7-[Methyl-(2-pyridin-2-yl-propionyl)-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10-yl}- acetic acid
Figure imgf000044_0001
5 The title compound was prepared using analogous procedures described in
Example 1 (Method A) from 2-(pyridin-2-yl)propanoic acid and propyl [(7J?)-7-(methylamino)- 6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. MS (+ESI) m/z: 392.
EXAMPLE 61
10 ((7^).4-Fluoro-7-{[(2R or 25)-2-(4-fluoro-phenyl)-propionyl]-methyl-amino}-6,7,8,9-tetrahydro- pyrido[l,2-a]indol-10-yl)-acetic acid
Figure imgf000044_0002
Step 1 : 7-fluoroindole
This compound was prepared from 2-fluoro-phenylhydrazine according to the
15 procedure outlined for propyl ([7R]-7-amino-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl)acetate. Step 2: propyl [(7R)-4-fluoro-7-(methylamino)-6,7,8,9-tetrahydropyrido [ 1 ,2-α]indol- 10- yl] acetate:
This compound was prepared from 7-fluoroindole according to the general procedures outlined in Example 1 (step 1 and 2).
20 Step 3: (Y7i?)-4-Fluoro-7-( \(2R or 25f)-2-(4-fluoro-phenvD-propionyll-methyl-aminol-
Figure imgf000044_0003
The title compound was prepared using analogous procedures described in Example 1 (Method A) from 2-phenylpropanoic acid and propyl [(7i?)-4-fluoro-7- (methylamino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetate. The chiral separation of the
25 resulting diastereoisomers was performed on chiral HPLC using a 4.6x25 Omm Chiralcel OD column eluting with 10% iPrOH, 89.75% Hexanes and 0.25% Et3N at lmL/min and 254nm. Retention times = 9.7 and 13.4min. The two resulting esters were hydrolyzed separately to afford EXAMPLE 61.1 and 61.2 respectively. MS (+ESI) m/z: 449. MCC-BRE-00003
BIOLOGICAL ASSAYS
Radioligand binding assay. Radioligand binding assays were performed at room temperature in 10 niM HEPES/KOH pH 7.4, ImM EDTA containing 1OmM MnCl2 and 0.7 nM 5 [3H]PGD2 (NEN, 171 Ci mmol"1), in a final volume of 0.2 ml. Competing ligands were diluted in dimethylsulfoxide (Me2SO) that was kept constant at 1% (v/v) of the final incubation volume. The reaction was initiated by the addition of 8-20 μg of membrane protein prepared from a HEK- hCRTH2 cell line. Total and non-specific binding were determined in the absence and the presence of 10 μM PGD2, respectively. Under these conditions, specific binding (total minus
10 non-specific) of the radioligand to the receptor reached equilibrium within 50 min and was stable up to 180 min. The reaction was routinely conducted for 60 min at room temperature and terminated by rapid filtration through prewetted Unifilters GF/C (Packard), using a Tomtec MachIII semi-automated harvester (for HEK-hCRTH2). The filters were then washed with 4ml of the same buffer and residual radioligand bound to the filter was determined by liquid
15 scintillation counting following equilibration in 25 μl Ultima Gold F™ (Unifilter) (Packard). The Ki (in nM) values for representative compounds of the present invention are as follows: <5: Examples 1, 3, 5, 6, 20, 30, 31, 32, 35; >5 and <10: Examples, 2, 26, 29; >10 and <50: Examples 9, 19, 21, 23, 25, 36; >50 and <100: Examples 7, 34. ifcAMP] measurements. HEK-hCRTH2 cells were grown to 80-90% confluency.
20 On the day of the assay, the cells were washed with PBS, incubated for 2 min in cell dissociation buffer, harvested by centrifugation at 300g for 5 min at room temperature and resuspended at 1.25elO6 cells ml"1 in Hanks' balanced salt solution containing 20 mM HEPES pH 7.4 and 0.75 mM IBMX (HBSS/HEPES/IBMX). The assay was performed in 384-plate format with 0.01 ml HBSS/HEPES/IBMX per well containing 12 500 cells and 75 nl of the test compound at various
25 concentrations. Following a 10 min pre-incubation of the cells with the test compound at 370C, 0.005 ml of Forskolin / DK-PGD2 dilute in HBSS 20 mM Hepes, was added at a respectively final concentration of 10 uM and 150 nM, to initiate the reaction. After 10 min incubation at 3700C, the cAMP content was quantified using the cAMP XS+ HitHunter chemiluminescence assay. (GE Healthcare 90-0075). % inhibition was calculated using the Forskolin and EC85 DK-
30 PGD2 controls.
Eosinophil shape change assay in human whole blood. Blood was collected in vacutainers containing EDTA. The antagonist was added to blood and incubated for 10 min at room temperature. DK-PGD2 (13,14-dihydro-15-keto prostaglandin D2) was then added to blood for 4 min at 370C in a running water bath. Blood cells were then fixed in presence of cold
35 0.25%(v/v) paraformaldehyde prepared in 75%(v/v) PBS for 1 min on ice. 175μL of fixed blood was transferred into 870μL of cold 155mM NH4Cl lysis solution and incubated at 40C for at least 40 min. The solution was then centrifuged at 43Og for 5min and the supernatant was discarded. Centrifuged cells were analyzed with a FACs Calibur flow cytometer (Becton Dickinson). Flow MCC-BRE-00003
cytometry raw data were analyzed with FlowJo software by isolating the eosinophils from the neutrophils based on their high autofluorescence and determining the percent of total eosinophils with increased FSC-H value. Maximum (100%) and minimum (0%) shape change were determined in the presence of lOμM DK-PGD2 and PBS, respectively. A dose response curve 5 with DK-PGD2 was performed with every assay to determine the EC50 for each blood donor. Compounds were tested in 10-dose titration curves in the presence of 3OnM DK-PGD2 to determine an antagonist IC50.
Some compounds of the present invention are selective for the CRTH2 receptor over the DP receptor. Assays on the DP, as well as other prostanoid, receptors are described in 10 WO2003/06220.

Claims

MCC-BRE-00003WHAT IS CLAIMED IS:
1. A compound of the formula I :
Figure imgf000047_0001
I and pharmaceutically acceptable salts thereof, wherein:
Y is selected from -C(Ra)(Rb)-, -C(Ra)(Rb)-C(Ra)(Rb)-, -C(Ra)=C(Rb)-, -OCH2-, -OCH(Ci-
3alkyl)-, -OC(Ci -3alkyl)2-, -OC(CH2)2-5-, -SCH2-. -SCH(Ci -3 alkyl)-, -SC(Ci-3alkyl)2- and - 10 SC(CH2)2-5-;
Z is -C(O)-(C(Rd)(Re))n- or -C(O)-C(Rf)(Rg)-O-, wherein n is O, 1 or 2;
Cy is aryl, heteroaryl or C3-6 cycloalkyl optionally fused to a benzene, each of which is optionally substituted with 1 to 4 groups independently selected from Rc; R1 is selected from H, halogen, -OCi-6alkyl, and -Ci-6alkyl;
15 R2 is selected from H, halogen, -C 1 -όalkyl, -OC 1 -6alkyl, -SCi -6alkyl, -S(O)C 1 -6alkyl, - S(O)2Ci-6alkyl, -CN, aryl and heteroaryl; R^ is selected from H, Ci-6alkyl and benzyl optionally substituted on the phenyl portion with 1 to 3 halogen;
Ra and Rb are independently H, aryl, heteroaryl, Ci.galkyl or haloCl-βalkyl; or
20 Ra and Rb together with the carbon atom to which they are both attached form a C3-6cycloalkyl ring; or
Ra and Rb together with the adjacent carbon atoms to which they are attached form a C3- gcycloalkyl ring;
Re is selected from halogen, NRfRg, Sθ2NRfRg, CN, Ci-6alkoxy, Ci-6alkyl, haloCi-6alkoxy, 25 and haloCi-6alkyl;
Rd and Re are independently selected from hydrogen, Ci_6alkyl, -Ci-6alkyl-C3_6cycloalkyl, hydroxy, C]-6alkoxy, aryl optionally substituted with 1 to 3 groups independently selected from
Rc, and NRfRg; or
Rd, Re together with the carbon atom to which they are both attached form a C3_6cycloalkyl
30 optionally having a ring heteroatom selected from -O-, -S-, -N(C(O)Rf)- and -N(Rf)-, and optionally substituted with 1 to 3 C]_3alkyl groups; or MCC-BRE-00003
Rd, Re attached to adjacent carbon atoms together with the carbon atoms to which they are attached form a C3-6cycloalkyl optionally having a ring heteroatom selected from -O-, -S-, - N(C(O)Rf)- and -N(Rf)-, and optionally substituted with 1 to 3 Ci_3alkyl groups; and Rf and Rg are independently selected from hydrogen and Ci_3alkyl; or 5 Rf Rg together with the atom to which they are both attached form a 3- to 6-membered ring.
2. A compound of Claim 1 wherein Cy is phenyl optionally substituted with 1 to 3 groups independently selected from Rc.
10 3. A compound of Claim 1 wherein Y is -C(Ra)(Rb)-.
4. A compound of Claim 1 wherein the moiety -Z-Cy represents -C(O)- C(Rd)(Re).phenyl wherein phenyl is optionally substituted with 1 to 2 groups independently selected from halogen, Ci-6alkyl, haloCi-6alkyl and Ci-6alkoxy.
15
5. A compound of Claim 1 wherein the chiral carbon to which the -NR3-Z- Cy is attached has the (^-configuration.
6. A compound of Claim 1 having the formula Ia:
Figure imgf000048_0001
Ia wherein Rl , R2, R35 and Rc are as defined in Claim 1.
7. A compound of Claim 1 having the formula Ib:
Figure imgf000048_0002
Ib wherein Rl, R2, R3, RC5 Rd and Re are as defined in Claim 1. MCC-BRE-00003
8. A compound of Claim 7 wherein Rd, Re and the carbon to which they are both attached together form a C3_6carbocycle optionally substituted with one or two Ci-3alkyl groups. 5
9. A compound of Claim 1 selected from the group consisting of:
{(7i?)-7-[[2-(4-fluorophenyl)propanoyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l ,2-α]indol- 10- yl} acetic acid; {(7i?)-7-[[(4-fluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-fl]indol-10-yl}-
10 acetic acid;
{{1 R)-I- { (4-fluorobenzyl) [(4-fluorophenyl)acetyl] amino } -6,7,8,9-tetrahydropyrido [ 1 ,2-α] indol-
10-yl)acetic acid;
[(7i?)-7-({[l-(4-fluorophenyl)cyclopentyl]carbonyl}amino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-
10-yl]acetic acid; 15 {(7i?)-7-[{[l-(4-fluorophenyl)cyclopentyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido [ 1 ,2-α]indol- 10-yl } acetic acid;
{(7i?)-7-[[2-(4-fluorophenyl)-2-methylpropanoyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l ,2- α]indol-10-yl}acetic acid;
{(7i?)-7-[[(2,4-difluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-a]indol-10- 20 yl}acetic acid;
{(7/?)-7-[[(2-chloro-4-fluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}- acetic acid;
{ (IR)-I- [ [(3-chloro-4-fluorophenyl)acetyl] (methyl)amino] -6,7,8,9-tetrahydropyrido [ 1 ,2-α]indol-
10-yl} acetic acid; 25 {(7i?)-7-[{[4-fluoro-2-(trifluoromethyl)phenyl]acetyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido [ 1 ,2-α]indol- 10-yl } acetic acid;
{(7i?)-7-[{[4-fluoro-3-(trifluoromethyl)phenyl]acetyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido[l,2-α]indol-l 0-yl} acetic acid;
{(7i?)-7-[(2,3-dihydro-lH-inden-l-ylcarbonyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]- 30 indol-10-yl} acetic acid;
{ (IR)-I- [ [4-(difluoromethyl)-3-iodobenzoyl](methyl)amino] -6,7,8 ,9-tetrahydropyrido [ 1 ,2-α] - indol-10-yl} acetic acid;
{(7i?)-7-[[(2-(2-bromo-4-fluorophenyl)propanoyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2- β]indol-10-yl}acetic acid; 35 {(7J?)-7-[(4-fluorobenzoyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
{(7i?)-7-[(cyclopentylcarbonyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid; MCC-BRE-00003
{(7i?)-7-[(cyclopropylcarbonyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
((7i?)-7-{methyl[(5-methylisoxazol-3-yl)carbonyl]amino}-6,7,8,9-tetrahydropyrido[l,2-α]indol-
10-yl)acetic acid; 5 (7Λ)-7-[[(4-chlorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l ,2-α]indol-l 0-yl}- acetic acid;
{(7i?)-7-[{[l-(4-chlorophenyl)cyclopentyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido [ 1 ,2-a] indol- 10-yl } acetic acid;
{(7J?)-7-[[(4-methoxyphenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}- 10 acetic acid;
{(7i?)-7-[methyl(phenoxyacetyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
{(7i?)-7-[methyl(phenylacetyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
{(7i?)-7-[methyl(2-naphthoyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
{(7i?)-7-[[(3,4-difluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10- 15 yl}acetic acid;
{(7J/?)-7-[(2,2-dimethyl-3-phenylpropanoyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-ύ!]indol-
10-yl} acetic acid;
[(7i?)-7-(methyl{[4-(trifluoromethyl)phenyl]acetyl}amino)-6,7,8,9-tetrahydropyrido[l,2-α]indol-
10-yl] acetic acid 20 {(7i?)-7-[methyl(l-naphthylacetyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
{(7i?)-7-[methyl(3-phenylpropanoyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
((T 'R)-I- {methyl[2-phenylpropanoyl]amino } -6,7,8,9-tetrahydropyrido[ 1 ,2-α]indol- 10-yl)acetic acid; 25 {(7i?)-7-[{[l-(4-fluorophenyl)cyclopropyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido [ 1 ,2-a] indol- 10-yl } acetic acid;
{(7i?)-7-[{[l-(4-fluorophenyl)cyclobutyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2- a] indol- 10-yl} acetic acid;
{(7i?)-7-[[2-(4-fluorophenyl)-2-piperidin-l-ylacetyl](methyl)amino]-6,7,8,9-tetrahydro- 30 pyrido[l,2-α]indol-10-yl}acetic acid;
{(7i?)-7-[[(2-bromo-4-fluorophenyl)acetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-
10-yl} acetic acid;
{(7i?)-7-[{[l-(4-fluorophenyl)-2,2-dimethylcyclopropyl]carbonyl}(methyl)amino]-6,7,8,9- tetrahydropyrido [ 1 ,2-α]indol- 10-yl } acetic acid; 35 {(7i?)-7-[[-2-methoxy-2-phenylacetyl](methyl)amino]-6,7,8,9-tetrahydropyrido[l ,2-α]indol-l 0- yl}acetic acid;
{(7i?)-7-[methyl-(2-thiophen-2-yl-acetyl)-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10-yl}- acetic acid; MCC-BRE-00003
{(7i?)-7-[methyl-(2-thiophen-3-yl-acetyl)-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10-yl}- acetic acid;
((7i?)-7- { [2,2-bis-(4-fluoro-phenyl)-acetyl] -methyl-amino } -6,7, 8,9-tetrahydro-pyrido [ 1 ,2-a] - indol-10-yl)-acetic acid; 5 {(7/f)-7-[(diphenylacetyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
{(7R)-7-[(diphenylacetyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl}acetic acid;
((7R)-7-{methyl-[2-(2-methyl-thiazol-4-yl)-acetyl]-amino}-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10-yl)- acetic acid;
((7/?)-7-{[2-(3,5-dimethyl-isoxazol-4-yl)-acetyl]-methyl-amino}-6,7,8,9-tetrahydro-pyrido[l,2- 10 a]indol-10-yl)-acetic acid;
((7R)-7-{[2-ethyl-2-(4-fluoro-phenyl)-butyryl]-methyl-amino}-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10- yl)-acetic acid;
{{1 R)-I- { [3 -cyclopropyl-2-(4-fluoro-phenyl)-propionyl] -methyl-amino } -6,7, 8,9-tetrahydro- pyrido[l,2-a]indol-10-yl)-acetic acid; 15 [(7/?)-7-{[(2i?)-2-hydroxy-2-phenylpropanoyl](methyl)amino}-6,7,8,9-tetrahydropyrido [1,2-α]- indol-10-yl]acetic acid;
[(7/?)-7-{[(25}-2-hydroxy-2-phenylpropanoyl](methyl)amino}-6,7,8,9-tetrahydropyrido[l,2-α]- indol-10-yl]acetic acid;
((7/?)-7-{ethyl-[l-(4-fluoro-phenyl)-cyclopropanecarbonyl]-amino}-6,7,8,9-tetrahydro- 20 pyrido[l,2-a]indol-10-yl)-acetic acid
[(7i?)-7-(methyl{[2-(pyridin-4-yl)cyclopropyl]carbonyl}amino)-6,7,8,9-tetrahydropyrido[l,2-α]- indol-10-yl]acetic acid;
{(7J?)-7-[(bicyclo[4.2.0]octa-l,3,5-trien-7-ylcarbonyl)(methyl)amino]-6,7,8,9-tetrahydro- pyrido[l,2-α]indol-10-yl}acetic acid; 25 {(7J/?)-7-[(imidazo[l,2-fl]pyridin-3-ylacetyl)(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2-α]indol-
10-yl} acetic acid;
[(7S)-7-{[(4-fluorophenyl)acetyl](methyl)amino}-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl]acetic acid;
((7i?)-7-{[4-(4-fluoro-phenyl)-tetrahydro-pyran-4-carbonyl]-methyl-amino}-6,7,8,9-tetrahydro- pyrido[l,2-a]indol-l O-yl)-acetic acid; 30 {(7R)-7-[(2-methoxy-2-phenyl-acetyl)-methyl-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10- yl}-acetic acid;
[(7/?)-7-{methyl[(2R or 2S)-2-phenylpropanoyl]amino}-6,7,8,9-tetrahydropyrido[l,2-a]indol-10-yl]acetic acid;
{(7R)-7-[methyl-( 1 ,2,3,4-tetrahydro-naphthalene- 1 -carbonyl)-amino]-6,7,8,9-tetrahydro-pyrido[ 1 ,2-a]- 35 indol- 10-yl} -acetic acid;
((7/?)-7-{[2-(4-dimethylamino-phenyl)-acetyl]-methyl-amino}-6,7,8,9-tetrahydro-pyrido[l,2-a]- indol- 10-yl)-acetic acid; MCC-BRE-00003
{(7i?)-7-[(2-cyclopentyl-acetyl)-methyl-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10-yl}- acetic acid;
((7i?)-7-{methyl-[3-(piperidine-l-sulfonyl)-benzoyl]-ammo}-6,7,8,9-tetrahydro-pyrido[l,2-a]- indol-10-yl)-acetic acid;
5 {(7i?)-7-[methyl-(2-pyridin-2-yl-propionyl)-amino]-6,7,8,9-tetrahydro-pyrido[l,2-a]indol-10-yl}-acetic acid; and
((7R)-4-flUoro-7-{[(2R or 2S)-2-(4-fluoropheny])-propionyl]-methyl-amino}-6,7,8,9-tetrahydro- pyrido[l,2-a]indol-l O-yl)-acetic acid, or a pharmaceutically acceptable salt thereof. 10
10. A compound of Claim 1 selected from the group consisting of:
{ (IR)-I- [ [2-(4-fluorophenyl)propanoyl] (methyl)amino] -6,7,8 ,9-tetrahydropyrido [ 1 ,2-a]indol- 10- yl}acetic acid;
((7i?)-7-{(4-fluorobenzyl)[(4-fluorophenyl)acetyl]amino}-6,7,8,9-tetrahydropyrido[l,2-α]indol- 15 10-yl)acetic acid;
{(7i?)-7-[{[l-(4-fluorophenyl)cyclopentyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido[l,2-α]indol-10-yl}acetic acid;
{ (IR)-I- [[2-(4-fluorophenyl)-2-methylpropanoyl] (methyl)amino] -6,7,8,9-tetrahydropyrido [ 1 ,2- α]indol-10-yl} acetic acid; 20 {(7i?)-7-[{[l-(4-chlorophenyl)cyclopentyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- pyrido[ 1 ,2-α]indol- 10-yl} acetic acid;
((7i?)-7-{methyl[2-phenylpropanoyl]amino}-6,7,8,9-tetrahydropyrido[l,2-α]indol-10-yl)acetic acid;
{(7i?)-7-[{[l-(4-fluorophenyl)cyclopropyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydro- 25 pyrido[l,2-α]indol-l 0-yl} acetic acid;
{(7i?)-7-[{[l-(4-fluorophenyl)cyclobutyl]carbonyl}(methyl)amino]-6,7,8,9-tetrahydropyrido[l,2- α]indol-10-yl}acetic acid; and
{ (7i?)-7-[ { [ 1 -(4-fluorophenyl)-2,2-dimethylcyclopropyl]carbonyl} (methyl)amino]-6,7,8,9- tetrahydropyrido[l,2-α]indol-10-yl}acetic acid, 30 or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.
35 12. Use of a compound of Claim 1 in the manufacture of a medicament for the treatment or prevention of CRTH2-mediated diseases.
PCT/CA2009/001321 2008-09-22 2009-09-17 Indole derivatives as crth2 receptor antagonists WO2010031183A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2009295230A AU2009295230A1 (en) 2008-09-22 2009-09-17 Indole derivatives as CRTH2 receptor antagonists
CA2737483A CA2737483A1 (en) 2008-09-22 2009-09-17 Indole derivatives as crth2 receptor antagonists
JP2011527166A JP2012502927A (en) 2008-09-22 2009-09-17 Indole derivatives as CRTH2 receptor antagonists
US13/120,074 US8637671B2 (en) 2008-09-22 2009-09-17 Indole derivatives as CRTH2 receptor antagonists
EP09813945.4A EP2346865B1 (en) 2008-09-22 2009-09-17 Indole derivatives as crth2 receptor antagonists

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US19278708P 2008-09-22 2008-09-22
US61/192,787 2008-09-22
US17243909P 2009-04-24 2009-04-24
US61/172,439 2009-04-24

Publications (1)

Publication Number Publication Date
WO2010031183A1 true WO2010031183A1 (en) 2010-03-25

Family

ID=42039054

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2009/001321 WO2010031183A1 (en) 2008-09-22 2009-09-17 Indole derivatives as crth2 receptor antagonists

Country Status (6)

Country Link
US (1) US8637671B2 (en)
EP (1) EP2346865B1 (en)
JP (1) JP2012502927A (en)
AU (1) AU2009295230A1 (en)
CA (1) CA2737483A1 (en)
WO (1) WO2010031183A1 (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
US8394819B2 (en) 2009-02-24 2013-03-12 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists
US8697869B2 (en) 2010-03-22 2014-04-15 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2017005759A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make azaindole derivatives
WO2017005766A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make tricycic alcohol intermediates of crth2 antagonists
US9850241B2 (en) 2014-03-18 2017-12-26 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US9879006B2 (en) 2014-03-17 2018-01-30 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms
WO2021123094A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
WO2023021171A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009295229B2 (en) * 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
ES2635030T3 (en) 2010-12-23 2017-10-02 Merck Sharp & Dohme Corp. Quinoxalines and aza-quinoxalines as modulators of the CRTH2 receptor
MX2013014900A (en) 2011-06-17 2014-02-17 Merck Sharp & Dohme Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators.
WO2016133793A1 (en) * 2015-02-16 2016-08-25 Merck Sharp & Dohme Corp. FACTOR IXa INHIBITORS

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384349A1 (en) * 1989-02-23 1990-08-29 F. Hoffmann-La Roche Ag Substituted pyrroles
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
WO1996001644A1 (en) 1994-07-11 1996-01-25 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
WO1996006108A2 (en) 1994-08-25 1996-02-29 Cytel Corporation Cyclic cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
WO1996020216A1 (en) 1994-12-24 1996-07-04 Zeneca Limited Fibronectin adhesion inhibitors
WO1996022966A1 (en) 1995-01-23 1996-08-01 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
WO1997003094A1 (en) 1995-07-11 1997-01-30 Biogen, Inc. Cell adhesion inhibitors
WO2007019675A1 (en) * 2005-08-12 2007-02-22 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039807A1 (en) * 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine and pyridoindolizine derivatives
WO2006125179A1 (en) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
WO2008147852A1 (en) * 2007-05-22 2008-12-04 Taigen Biotechnology Co., Ltd. Kinesin inhibitors
RU2451019C2 (en) 2007-10-10 2012-05-20 КЕМИТЕК, ЭлЭлСи Heterocyclic compounds as crth2 receptor antagonists
US8546422B2 (en) * 2008-09-22 2013-10-01 Merck Canada Inc. Azaindole derivatives as CRTH2 receptor antagonists
AU2009295229B2 (en) 2008-09-22 2014-02-27 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
US8394819B2 (en) * 2009-02-24 2013-03-12 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384349A1 (en) * 1989-02-23 1990-08-29 F. Hoffmann-La Roche Ag Substituted pyrroles
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
WO1996001644A1 (en) 1994-07-11 1996-01-25 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
WO1996006108A2 (en) 1994-08-25 1996-02-29 Cytel Corporation Cyclic cs-1 peptidomimetics, compositions and methods of using the same
WO1996020216A1 (en) 1994-12-24 1996-07-04 Zeneca Limited Fibronectin adhesion inhibitors
WO1996022966A1 (en) 1995-01-23 1996-08-01 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (en) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
WO1997002289A1 (en) 1995-07-06 1997-01-23 Zeneca Limited Peptide inhibitors of fibronectine
WO1997003094A1 (en) 1995-07-11 1997-01-30 Biogen, Inc. Cell adhesion inhibitors
WO2007019675A1 (en) * 2005-08-12 2007-02-22 Merck Frosst Canada Ltd. Indole derivatives as crth2 receptor antagonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIT ET AL.: "Inhibitors of Protein Kinase C. 3. Potent and Highly Selective Bisindolylmaleimides by Conformational Restriction", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 1, 1993, pages 21 - 29, XP002583362 *
See also references of EP2346865A4

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8394819B2 (en) 2009-02-24 2013-03-12 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists
US9023864B2 (en) 2009-02-24 2015-05-05 Merck Sharp & Dohme Corp. Indole derivatives as CRTH2 receptor antagonists
US8697869B2 (en) 2010-03-22 2014-04-15 Actelion Pharmaceuticals Ltd. 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators
WO2012069175A1 (en) 2010-11-25 2012-05-31 Almirall, S.A. New pyrazole derivatives having crth2 antagonistic behaviour
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
KR101928595B1 (en) 2011-04-14 2018-12-12 이도르시아 파마슈티컬스 리미티드 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
WO2012140612A1 (en) 2011-04-14 2012-10-18 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
AU2012241442B2 (en) * 2011-04-14 2017-01-12 Idorsia Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido(1,2-a)indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
RU2596823C2 (en) * 2011-04-14 2016-09-10 Актелион Фармасьютиклз Лтд DERIVATIVES OF 7-(HETEROARYL-AMINO)-6,7,8,9-TETRAHYDROPYRIDO[1,2-a]INDOLE-ACETIC ACID AND USE THEREOF AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
CN103459389A (en) * 2011-04-14 2013-12-18 埃科特莱茵药品有限公司 7-(heteroaryl-amino)-6, 7, 8, 9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
US9096595B2 (en) 2011-04-14 2015-08-04 Actelion Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators
JP2014510784A (en) * 2011-04-14 2014-05-01 アクテリオン ファーマシューティカルズ リミテッド 7- (Heteroaryl-amino) -6,7,8,9-tetrahydropyrido [1,2-a] indoleacetic acid derivatives and their use as prostaglandin D2 receptor modulators
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
WO2013010881A1 (en) 2011-07-18 2013-01-24 Almirall, S.A. NEW CRTh2 ANTAGONISTS
WO2013010880A1 (en) 2011-07-18 2013-01-24 Almirall, S.A. New crth2 antagonists
US10301309B2 (en) 2014-03-17 2019-05-28 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US9879006B2 (en) 2014-03-17 2018-01-30 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
US9850241B2 (en) 2014-03-18 2017-12-26 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
WO2016156588A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
EP3954710A2 (en) 2015-04-02 2022-02-16 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
WO2017005759A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make azaindole derivatives
WO2017005766A1 (en) 2015-07-07 2017-01-12 Intervet International B.V. A process to make tricycic alcohol intermediates of crth2 antagonists
US10351560B2 (en) 2015-09-15 2019-07-16 Idorsia Pharmaceuticals Ltd Crystalline forms
WO2021123094A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
WO2021123092A1 (en) 2019-12-20 2021-06-24 Intervet International B.V. Bispecific caninized antibodies for treating atopic dermatitis
WO2023021171A1 (en) 2021-08-20 2023-02-23 Intervet International B.V. Homodimer fusion proteins for treating atopic dermatitis
WO2023021170A2 (en) 2021-08-20 2023-02-23 Intervet International B.V. Fusion proteins for treating atopic dermatitis

Also Published As

Publication number Publication date
AU2009295230A1 (en) 2010-03-25
US20110172263A1 (en) 2011-07-14
CA2737483A1 (en) 2010-03-25
EP2346865A4 (en) 2012-05-23
EP2346865A1 (en) 2011-07-27
EP2346865B1 (en) 2015-07-15
US8637671B2 (en) 2014-01-28
JP2012502927A (en) 2012-02-02

Similar Documents

Publication Publication Date Title
EP2346865B1 (en) Indole derivatives as crth2 receptor antagonists
EP2344497B1 (en) Azaindole derivatives as crth2 receptor antagonists
US7696222B2 (en) Indole derivatives as CRTH2 receptor antagonists
EP1305286B1 (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
EP2197438B1 (en) Heterocyclic compounds as crth2 receptor antagonists
EP2492267B1 (en) Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient
WO2010031182A1 (en) Indole derivatives as crth2 receptor antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09813945

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009295230

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2011527166

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009813945

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2737483

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13120074

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009295230

Country of ref document: AU

Date of ref document: 20090917

Kind code of ref document: A